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SUMMARY
The lite ra tu re  describing the role o f the cholinergic system and opioids on 
antinociception is reviewed. The e ffec ts  o f anticholinesterase agents and drugs 
used in the treatm ent o f anticholinesterase poisoning were studied fo r the ir 
e ffects  on opioid antinociception and locomotion. In both mice and rats, the 
irreversib le anticholinesterase, DFP, produced apparent antinociception, but only 
at doses which caused m otor incapacita tion. P re-trea tm ent w ith  DFP 
potentiated the antinociceptive potency of the opioid drug a lfen tan il but had 
li t t le  e ffe c t on morphine or fentanyl using the hot-p la te test in m ice. The 
reversible anticholinesterases, neostigmine and pyridostigm ine, did not a ffe c t 
a lfen tan il antinociception in this species. In rats, DFP potentiated a lfen tan il and 
fentanyl antinociception using the paw pressure test, but had no e ffe c t on 
morphine. In m ice, drugs used to trea t anticholinesterase poisoning (atropine, 
pralidoxime and diazepam) did not a lte r the e ffe c t o f DFP on a lfen tan il 
antinociception. DFP produced a decrease in locom otor a c tiv ity  in m ice which 
was reversed fo llow ing atropine and pralidoxime adm in istration. DFP decreased 
the hyperlocomotory a c tiv ity  o f a lfen tan il in m ice, probably by increasing 
a lfen tan il catatonia, but had l i t t le  e ffe c t on morphine or fentanyl. When 
diazepam was administered as part o f the trea tm ent fo r anticholinesterase 
poisoning, locomotor scores o f opioid treated mice were markedly reduced. In 
mice radiolabelled d istribu tion studies showed that DFP trea tm ent enhanced the 
entry of a lfen tan il into a ll brain regions, w hilst morphine and fen tanyl levels 
were unaltered. Studies on plasma protein binding o f a lfen tan il showed this was, 
in part, due to a displacement o f a lfen tan il bound to plasma proteins by DFP, 
enabling free drug to enter the brain. These studies suggest tha t fentanyl would 
least like ly  produce in teraction in individuals poisoned by irrevers ib le  
anticholinesterase agents. In addition, the new opioid drug, a lfen tan il, may be 
liable to interactions when used clin icall^w ith other drugs by displacement from  
plasma protein binding sites to a lte r its  antinociceptive a c tiv ity .
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CHAPTER 1 
INTRODUCTION
1.1 General In troduction
Opioids have been used by humans fo r many thousands o f years. Opium was 
f irs t  used around 4000 BC when i t  was mixed w ith  wine by the Sumerians. Its 
popularity as a drug remained, and is re flec ted  by Sydenham who, in 1680, 
w rote 'among the remedies which i t  has pleased A lm ighty  God to give to  man 
to relieve his suffering, none is so universal and efficacious as opium1. The 
main active constituent o f opium, morphine, is s t i l l  used therapeu tica lly  as 
the standard analgesic against which new agents are compared.
Despite Sydenham's praise, the therapeutic use o f opioids have a number o f 
drawbacks, the most im portant o f which are respiratory depression and a 
dependence lia b ility . Even though there has been extensive research in the 
development of novel opioids, these problems have not been com plete ly 
overcome. Another approach has involved the investigation o f non-opioid 
drugs which either possess inherent analgesic a c tiv ity  or are able to 
potentia te the desirable (analgesic) but not the undesirable action o f opioids. 
Cholinergic drugs, such as anticholinesterase agents, have received a lo t o f 
a ttention in this area and the ir in te raction  w ith  opioids and nociceptive 
systems is considered in Section 1.6.
1.2 Choice o f Drugs Used
Three opioids were used in the studies. Morphine as the standard analgesic 
agent, and two synthetic opioids, fentanyl and a lfen tan il. These la tte r  two 
are of a new generation of opioids which are very potent and are extrem ely 
rapid ly acting. These factors make them suitable fo r use as intravenous (i.v .) 
analgesics for use in surgery. The structure o f these opioids is given in 
Figure 1.1.
FENTANYL
,  , h  n , o  i co-oh » i oh ■ o i c h  . c o o n ;. .  c f h .  : *•
ALFENTANIL l?4h3?n?0;'CHr°-CH,
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Fig. 1.1. Three-dimensional Structures and 
Formulae of Morphine, Fentanyl 
and Alfentanil
Three anticholinesterases were used though the compound d i­
isopropylfluorophosphate (DFP) was investigated most thoroughly. 
Anticholinesterases are considered fu rthe r in the next Section.
1.3. Uses of Anticholinesterases
Anticholinesterases inh ib it the cholinesterase enzyme which results in a 
build-up of excessive acetylcholine. The therapeutic and tox ic  e ffec ts  o f 
these compounds are due to the accumulation of acetylcholine a t muscarinic 
and n ico tin ic  cholinergic receptors (Karczmar, 1967).
Anticholinesterases are norm ally divided into two groups, reversible and 
irreversib le , which correspond to carbamyl esters and organo-phosphorous 
compounds respectively. However both classes o f drugs react w ith  the 
cholinesterase enzyme in the same way, and so this c lassification re fle c ts  
only quantita tive differences. There are, in fac t, very few tru ly  reversible 
compounds and even neostigmine is not considered to be in this class (Usdin, 
1970). Nevertheless, fo r the sake of c la r ity  this classification w ill be used in 
the fo llow ing discussion.
1.3.1. Reversible Anticholinesterases: C lin ica l Uses
Therapeutically, reversible anticholinesterases are indicated in certa in  
neuromuscular abnormalities such as myasthenia gravis, where neuromuscular 
transmission is to be enhanced (see B ritish  National Form ulary, 1983). 
Neostigmine, pyridostigm ine, ambenonium, physostigmine and distigm ine are 
the anticholinesterases prescribed fo r myasthenia gravis, pyridostigm ine 
reported to have the fewest side-effects.
These drugs are also used to trea t urinary re tention, and because they 
increase in testina l m o tility , they may be used as stim ulant laxatives 
pa rticu la rly  post-operative ly in case o f para ly tic  ileus.
Probably the most common use fo r this class o f drug is in surgery. Non- 
depolarising muscle relaxants which are used as a premedication in surgery, 
compete fo r the acetylcholine receptor at the neuromuscular junction. The ir 
action may be reversed by increasing the synaptic concentration o f 
acetylcholine w ith  anticholinesterases. The usual drugs used to reverse post 
operative muscle re laxation are neostigmine and pyridostigm ine.
Anticholinesterases are also used in the trea tm ent o f glaucoma and indeed 
the f irs t therapeutic use fo r this class o f drug was when physostigmine was 
used fo r glaucoma (Laquer, 1877). Physostigmine is s t il l used fo r this purpose.
Reversible anticholinesterases are also used in the trea tm en t o f 
anticholinesterase poisoning (see Section 1.3.3.).
1.3.2. Reversible Anticholinesterases: N on-clin ica l Uses
The major non-clin ica l use fo r reversible anticholinesterases is as 
insecticides. Since the ir development in the 1950's, compounds such as 
carbamyl and propoxur have been used extensively fo r the ir highly selective 
insectic idal action.
1.3.3. Irreversib le  Anticholinesterases: C lin ica l Uses
The f irs t organophosphorous anticholinesterase agent was synthesised in the 
1850's (De Clerm ont, 1854). The f ir s t  therapeutic use, however, was only 
made some hundred years la te r when DFP was used to tre a t glaucoma
(Quillam , 1947). DFP became the drug o f choice in the trea tm ent o f 
glaucoma as i t  had the advantage over the carbamate drugs in tha t i t  was 
very long acting and could therefore be applied in frequently. However, i t  
was established some years la te r that continued trea tm ent w ith  long acting 
anticholinesterase agents carried a high risk o f a specific type o f ca ta ract 
(Axelsson and Holmberg, 1966). C urrently  in the UK the only 
organophosphorous compound used therapeutica lly, fo r the trea tm ent o f 
glaucoma, is ecjhiopiate.
1.3.4. Irreversible Anticholinesterases: N on-clin ica l Uses
As fo r reversible anticholinesterases, the irreversib le organophosphorous 
agents are extensively used as agricu ltu ra l insecticides. The f irs t  
organophosphorous compound synthesised, te trae thy l pyrophosphate (TEPP) 
(De C lerm ont, 1854), has been used as an insecticide though in recent years, 
more selective agents have been developed. One of the most w idely used 
insecticides is parathion, and this compound also probably accounts fo r more 
accidental poisonings and fa ta lit ie s  than any other organophosphorous 
compound (Koelle, 1985). Even more selective compounds were developed to 
reduce the toxico logica l risk to humans. For example, malathion has a UD^g 
mouse:LD^g housefly ra tio  o f 68 compared to only 6 fo r parathion (Usdin, 
1970).
1.3.5. Anticholinesterases as Chemical Warfare Agents
The potentia l fo r anticholinesterases as chemical warfare agents was realized 
in it ia lly  in Germany by Lange in 1935 (Karczmar, 1970). This was fo llowed by 
the synthesis and investigation o f new compounds (tabun and sarin) developed 
specifica lly  fo r the ir to x ic ity . Though these compunds were synthesised on a 
large scale, they were never actually deployed due to the fear of re ta llia tio n  
by A llied  forces using the ir own organophosphates.
Work on chem ical warfare agents continued in post-war years, though 
research proceeded at a low level, and B rita in  stopped its development o f 
new compounds in the 1950's. However, the USA, USSR and France s t il l 
manufacture these compounds so the development o f e ffe c tive  antidotes is an 
im portant area of reseach.
P rotection against organophosphorous poisoning may be afforded by the 
adm in istration o f several agents. The prophylactic e ffe c t o f carbamates has 
been known fo r some tim e (Koster, 1946). Research in subsequent years has 
shown tha t many carbamates pro tect against poisoning e ffe c tive ly , and tha t 
a c tiv ity  is dependent on many factors such as absorption, d is tribu tion  and 
metabolism (Gordon et al, 1978). The mechanism fo r the pro tective  action o f 
carbamates is dependent p rim arily  on the form ation o f a semi-stable 
carbamylated acetylcholinesterase; the enzyme in th is state cannot be 
phosphorylated by an organophosphate. The carbamylated enzyme can 
spontaneously break down to release the active enzyme (Wilson e t al, 1960) 
and as the organophosphate is broken down re la tive ly  rapid ly, su ffic ien t 
released enzyme is present to maintain life  (Berry and Davis, 1970).
Further protection from  organophosphate poisoning may be achieved by 
pharmacologically antagonising the e ffects  o f excess acetylcholine, by 
adm inistering an anticholinergic such as atropine. In addition, the inh ib ited 
cholinesterase enzymes may be reactivated by the adm in istra tion o f oxime 
such as pralidoxime mesylate. This is achieved by accelerating the 
spontaneous reactiva tion o f the inhib ited cholinesterase by prom oting 
hydrolysis o f the inhib itor-enzym e complex (Wills, 1970). This additional 
trea tm ent w ith  an oxime enhances the pro tective  potency of the carbamate 
and anticholinergic regimen (Gordon et al, 1978).
The most recent addition to the ba tte ry  o f drugs used to tre a t 
organophosphate poisoning is diazepam. I t  has been shown to greatly  enhance 
the pro tective  a c tiv ity  of atropine against physostigmine le th a lity  in mice 
(Klemm, 1983). I t  is believed to have this e ffe c t by v irtue  o f its  a n ti­
convulsant a c tiv ity . I t  does have the disadvantage, however, o f im pairing 
m otor function and performance (Gall, 1981; Fig. 1.2.).
1.4. Aim of the Study
The in it ia l objective o f the research described in this thesis was to study 
potentia l in teractions between irreversib le anticholinesterase agents and 
opioid analgesics, in an a ttem pt to h ighlight drug in teraction problems which 
m ight occur in individuals poisoned w ith  anticholinesterase agents, trea ted 
fo r such poisoning and given opioid drugs fo r the re lie f o f pain. This s ituation 
is c learly most pertinent in a m ilita ry  context, i f  in the fie ld , personnel 
exposed to organophosphorous compounds and receiving antidotes also sustain 
in juries requiring surgery. In a broader sense, the aim of this thesis was to 
study the nature and a ttem pt to analyse the mechanisms of in te rac tion  
between opioids and anticholinesterase agents.
1.5. T erminoloqy
In this thesis, in describing the e ffects  o f opioids on pain responses in 
animals, the term  'antinociception1 is used, as d is tinc t from  the word 
'analgesia' used in the human context.
Analgesia is defined as 'absence of pain' and pain as 'suffering distress o f body 
or mind' (Oxford English D ictionary). As suffering and distress are subjective
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phenomena, animals therefore cannot be described as perceiving pain per se. 
However, they are able to sense and respond to noxious stim u li, so the terms 
'nociception' and 'antinociception ' are used.
The term  'opioid' has been used throughout this thesis to describe analgesic 
drugs. This is d is tinc t from  the term  'opiate', the use o f which should be 
confined to those products o f the opium poppy and re lated synthetic 
alkaloids. 'Opioid' describes a ll drugs which are opiate-like in th e ir action 
(see K itchen, 1984).
1.6. A Review of the Literature on the Role of the Cholinergic
System and Opioids on Antinociception
1.6.1 Introduction
The potentia ting e ffe c t o f anticholinesterase agents on the a c tiv ity  o f opioid 
analgesics has been known fo r several years (Flodmark and Wramner, 1945; 
Slaughter, 1950) and there is now a large body o f lite ra tu re  describing the 
in te raction  between cholinergic agents and opioids. This review summarizes 
the present lite ra tu re  and suggests mechanisms underlying in teractions.
Most o f the available lite ra tu re  concerns work using animal models o f pain 
perception though there are reports fo r human models and fo r c lin ica l pain, 
and i t  is these studies which indicate a potentia l therapeutic ro le fo r 
cholinergic agents in enhancing the desirable analgesic e ffects  o f opioids, 
w h ilst reducing the undesirable components such as respiratory depression. 
Furthermore, these studies have gone someway in elucidating the physiology 
o f pain perception and have indicated possible fu tu re  developments in the 
pharmacology o f pain contro l. .
1.6.2. Nociceptive Models
The assessment o f the potency o f analgesic drugs is usually in it ia lly  carried 
out in experimental animals. A varie ty  o f tests have been developed, using 
several animal species to determine the antinociceptive a c tiv ity  o f drugs and 
a b rie f description of the tests described in this review is given in Table 1.1.
Even though a ll the models described are responsive to opioids, i t  is 
im portant to consider that differences in the nociceptive s tim u li (heat, 
pressure, e lec trica l) may well involve d is tinc t pathways u tiliz ing  d iffe re n t 
neurotransm itters and that processing o f nociceptive in form ation may vary
TABLE 1.1. METHODS OF NOCICEPTIVE ASSESSMENT
Test Species Method of 
nociceptive stim ulation
End-point or 
quantifica tion
Reference
Hot plate Rat
Mouse
Animals placed on 
heated m etal plate 
(48 to 55°C)
L ift in g , shaking 
or lick ing  paw, 
or jumping
Woolfe and
MacDonald,
1944.
Tail f lic k Rat
Mouse
Cat
Tail exposed to 
localized heat source 
e.g. focussed ligh t
F licking o f ta il 
away from  heat
D'Amour and 
Smith,
1941.
Tail immersion Rat
Mouse
Term inal part of
ta il immersed in water
(50-55°C)
F lick ing or 
lif t in g  ta il out 
o f water
Janssen 
et al., 
1963.
Hot wire Rat Tail heated by 
hot w ire
F lick ing o f ta il 
away from  heat
Davies 
et al., 
1946.
Tail c lip Rat
Mouse
Rabbit
Cat
Application of 
pressure by a c lip  
on base o f ta il
A ttem p t to b ite 
or remove clamp. 
Quantalresponse
H affner,
1929.
W rithing Mouse Intraperitoneal 
in jection o f ir r ita n t 
substance (e.g. acetic 
acid, phenoxybenzo- 
quinone)
Number o f 
abdominal 
constrictions 
observed in 
set perioid
Hendershot
and
Forsaith,
1939.
Form alin test Rat
Cat
Subcutaneous in jection 
o f 5% form alin  into 
forepaw pad
Scoring of 
in tensity and 
duration o f 
lif t in g , lick ing , 
shaking o f paw
O'Keefe,
1964.
Paw pressure Rat Pressure applied to 
normal or inflamed hind 
paw. Pressure increasing 
w ith  tim e
W ithdrawal o f 
foo t, struggling 
or vocalization
Randall and
S e litto ,
1957.
Ear clamp Rabbit
Dog
Varying pressure applied 
by clip on ear
A ttem p t to 
w ithdraw  or 
vocalization
Weinstock,
1980.
Toe pinch Guinea
pig
Cat
Prim ate
Varying pressure applied 
by clip on toe
A ttem p t to 
w ithdraw  or 
vocalization
C o llie r,
1962.
Test Species Method of End-point or Reference
nociceptive stim ulation quantification
Electroshock
Shock
titra t io n
Tail
e lec trica l
stim ulation
Tooth pulp 
e lec trica l 
stim ulation
Radiant heat
Note:
Rat Application o f e lec tric
Mouse current, usually to
fee t
Rat E lec tric  current to
Mouse feet w ith  stepwise
Prim ate increase in current
w ith  tim e
Rat E lec tric  current via
Mouse electrodes in
base o f ta il
Rabbit E lec tric  stim ulation
to upper incisors
Many Part o f skin (may
Species be blackened) exposed 
(eg. dog, to intense focussed
human) ligh t or laser
Vocalization, Evans,
vocalization 1961.
a fte r discharge
or w ithdrawal
o f paws
Time spent at Weiss and
each shock level Laties,
before 1970.
responding by
pressing lever
to reduce current
As fo r ta il Carol and
clamp or L im ,
electroshock 1960.
Threshold to H o ffm e is te r
jaw opening or 1968.
lick ing  response
Varies w ith Hardy
species: escape et al., 1940.
response (Human
(rodent), skin testing)
tw itc h  (dog),
verbal report
(human)
References re fe r to the f irs t report o f a particu la r method, or to  a w idely used 
adaptation o f a method. There are o f course, numerous variations and 
refinem ents o f many of the tests given in this table.
between species. Modulation of nociception by some drugs may, therefore, 
be test and species dependent. In addition some opioid receptor selective 
agonists exhib it varying degrees o f antinociception depending on the test 
used. For example, k-op io id  agonists are more e ffec tive  against pressure 
than therm al s tim u li (Tyers, 1980).
1.6.3. Anticholinesterases and Antinociception
a) Neostigmine
The f irs t studies o f the antinociceptive a c tiv ity  o f anticholinesterase in man 
were carried out by Flodmark and Wramner (1945). They showed 
neostigmine, a quaternary reversible anticholinesterase, had antinociceptive 
a c tiv ity  and also potentiated morphine antinociception. A s im ila r 
potentia tion was observed fo r other opioids (Slaughter, 1950). In contrast to 
man, animal studies have fa iled to show antinociceptive a c tiv ity  o f 
neostigmine (Saxena and Gupta, 1957). However, there are reports of 
potentia tion by neostigmine o f morphine antinociception (Knoll and Komlos, 
1952; Saxena and Gupta, 1957). These observations have not been confirm ed 
by other workers except when neostigmine is administered i.c .v . (Pedigo e t 
al., 1975). By this route the antinociception is antagonised by naloxone and 
atropine but not mecamylamine indicating tha t both opioid and muscarinic 
systems mediate the e ffe c t (Pedigo et al., 1975).
As the quaternary compound neostigmine does not readily cross the blood- 
brain barrier i t  exerts its action peripherally fo llow ing systemic in jection . I t  
is possible that the potentia tion o f opioids may be due to im paired 
metabolism or altered d istribution. The observed antinociceptive e ffe c t in 
humans (Flodmark and Wramner, 1945) may be due to the test used (radiant 
heat). As the authors suggest, neostigmine may increase cutaneous blood 
flow  and so dissipate the radiated heat more rapid ly. A lte rna tive ly , there 
may be an e ffe c t on peripheral pain sensitive neurons.
b) Physostiqmine
Table II shows tha t physostigmine is reported to possess antinociceptive 
a c tiv ity  in most o f the tests described. Most o f the reports showing no 
antinociceptive a c tiv ity  involved centra l adm in istration o f physostigmine. 
Since physostigmine readily crosses the blood-brain barrier, the lack o f e ffe c t 
o f centra l adm in istra tion suggests tha t physostigmine may be m etabolized in 
the periphery to the active compound. Indeed, FUrst et al. (1982) studied the 
antinociceptive a c tiv ity  o f eseroline, the prim ary m etabolite  o f 
physostigmine, and showed i t  to be a naloxone reversible analgesic when 
administered either peripherally or cen tra lly . The structure o f eseroline is 
s im ilar to morphine and the antinociceptive e ffe c t appears independent o f its  
anticholinesterase a c tiv ity .
Studies w ith  atropine and hyoscine (Harris et al., 1969; Wong and Bentley, 
1978; Dayton and G arret, 1973) and naloxone (Harris e t al., 1969; Romano 
and King, 1981) indicate tha t physostigmine exerts its  action through e ither 
the cholinergic or opioid system or both. The a b ility  o f naloxone to 
antagonise physostigmine was not found in some studies (Pleuvrey and Tobias, 
1971; Lipman and Spencer, 1980; Conzantis e t al., 1983) and has even been 
shown to potentia te physostigmine (Romano and King, 1981). O ther evidence 
suggesting tha t physostigmine’s e ffe c t may be independent of the opioid 
system are that tolerance may be induced fo llow ing m ultip le  adm inistrations 
o f physostigmine, w hilst morphine antinociception is not a ffected by this 
regimen (Dayton and G arret, 1973; L it t le  and Rees, 1974). In studies in the 
rhesus monkey, physostigmine appears to increase morphine antinociception 
(Pert, 1975). However, this e ffe c t is observed only at doses tha t also 
produced general behavioural depression.
The antinociceptive e ffects  of physostigmine may be inhib ited by 
pre trea tm ent w ith  compounds depleting centra l 5-HT (Bhattacharya and 
Nayak, 1978). 5-HT has been im plicated in antinociception (Messing and 
Ly tle , 1977), and may be part o f a pathway also involving cholinergic neurons. 
I t  is worth considering tha t the neurotoxins used to deplete 5-HT do not have 
absolute spec ific ity  and may w e ll disrupt other systems.
Widman et al. (1978) described the e ffe c t o f cen tra lly  administered calcium
ry
chloride on physostigmine antinociception. They observed tha t Ca + ions
n
reduced antinociception, and conclude that Ca + appeared to exert its  
e ffec ts  intraneuronally and postsynaptically. D ivalent ions are also involved 
in acetylcholine induced antinociception (Section 1.6.6.(c)) and are also 
discussed in Section 1.6.8.
1.6.4 Irreversible Anticholinesterases
Diisopropylfluorophosphate (DFP) has been investigated by several workers. 
In studies w ith  m ice, DFP was not found to be antinociceptive by one group 
up to 2 mg/kg (Cox and Tha, 1972). Morphine and fentanyl antinociception 
appear unaffected by DFP, but a lfen tam il antinociception is potentia ted 
(K itchen and Green, 1983). Bhargava and Way (1972), however, did conclude 
that DFP does potentia te morphine antinociception, though the e ffe c t was 
not s ta tis tica lly  s ign ificant.
The e ffe c t of DFP in rats has been studied thoroughly by one group (Koehn 
and Karczm ar, 1977; Koehn and Karczm ar, 1978; Koehn et al., 1980). They 
have determined that DFP has antinociceptive a c tiv ity  in hot plate and ta il 
f lic k  tests from  0.5 mg/kg. Antagonist studies indicate that this e ffe c t is 
mediated through both cholinergic and opioid systems. DFP's antinociceptive
action was stereoseiectively inhib ited by (-)benzomophan antagonists. The 
(+)isomers were e ffe c tive  only to a much lesser degree. The role o f this 
stereose lectiv ity  is considered fu rthe r in section 1.6.6. It is worthy o f note, 
however, that in animals made to leran t to morphine, DFP's e ffe c t was 
unaltered (Koehn et al., 1980). Saxena (1958) fa iled to show an 
antinociceptive e ffe c t o f DFP in rats, or any morphine potentia ting a c tiv ity . 
This may be due e ither to the u tiliza tio n  o f pressure as the nociceptive 
stimulus, or the lower dose (200 ug/kg) employed.
Clement and Copeman (1984) have studied the very potent anticholinesterase 
agents, soman and sarin. Both these agents produce antinociception that 
persists fo r up to 96 hours a fte r adm in istration. Further studies w ith  soman 
showed only an additive e ffe c t w ith  morphine, and tha t naloxone was only a 
pa rtia l antagonist up to 10 mg/kg, whereas atropine com plete ly antagonised 
soman's e ffe c t at 2.2 mg/kg. This in form ation suggests tha t a t least some of 
soman's antinociceptive a c tiv ity  is exerted through non-opioid systems.
1.6.5. Other Anticholinesterase Agents
There are a few reports concerning antinociceptive ac tiv itie s  o f some less 
fam ilia r anticholinesterase compounds, some of which are natura lly  occurring 
plant products. Galanthamine is a natural alkaloid, isolated from  
Am aryllidaceae, which possesses anticholinesterase a c tiv ity . I t  also has a 
chemical structure s im ilar to codeine. Its antinociceptive a c tiv ity  has been 
studied in the ra t hot plate and the mouse w rith ing tests (Cozantis et al., 
1983). In both these models galanthamine was antinociceptive, and was 
shown to be able to potentia te morphine antinociception in the ra t. Its mode 
o f action appears to be species dependent: its  antinociceptive a c t iv ity  is
antagonized by naloxone (0.1 mg/kg) in the ra t, but is re frac to ry  to naloxone
up to 0.5 mg/kg in the mouse. I t  is also possible that the nociceptive stimulus 
may be a determ ining fac to r as to whether the action of galanthamine is 
opioid mediated.
Tetrahydroam inoacridine (THA) was found to be inactive up to 3 mg/kg in the 
mouse hot plate antinociceptive test (Wooten and Klemm, 1980) though i t  
appears to prolong the antinociceptive e ffects  o f morphine. Using a higher 
dose o f 7.5 mg/kg and a d iffe re n t test model, Wong and Bentley (1978) 
observed antinociceptive a c tiv ity  fo r THA which was pa rtia lly  antagonized by 
atropine at 2 mg/kg. THA also potentiated the action o f morphine; th is 
action was also antagonized by atropine, and in addition the antagonistic 
a c tiv ity  o f naloxone was enhanced w ith  THA pretreatm ent.
A n tinociceptive  e ffects  of dibromopyruvic' acid have been reported (M artin  et 
al., 1958). This compound has weak anticholinesterase a c tiv ity  (1/400 tha t o f 
neostigmine) and may also possess muscarinic agonist a c tiv ity . However, its  
antinociceptive a c tiv ity  was not blocked by atropine at 2 mg/kg. Ibogaine is 
an indole alkaloid from  Tubernanthe iboqa and is able to in h ib it 
cholinesterase (Vincent and Sero, 1942). Though ibogaine its e lf is not 
antinociceptive up to 40 mg/kg, lower doses are able to potentia te morphine 
antinociception and le th a lity  (Schneider and M cArthur, 1956).
Recently, the organophosphorus insecticide tr io rth o to ly l phosphate has been 
reported to produce a s ix-fo ld  potentia tion o f heroin's potency in the mouse 
w rith ing  test (Cohen, 1984).
1.6.6. Cholinom im etics and Antinociception
a) Muscarinic Agonists
The data fo r oxotremorine shown in Table 1.3. clearly shows that i t  is able to 
induce antinociception in four species using many forms o f nociceptive 
stim ula tion. Only the ra t paw pressure test fa iled to show clear 
antinociceptive a c tiv ity  as the e ffec ts  were small and variable (B ill e t al.,
1983). Oxotremorine has been shown to be very potent on a molar basis in a ll 
the studies shown, w ith  an ED5Q as low as 11 ug/kg being reported by Metys 
et al., 1969. I t  appears to exert its  action through both cholinergic and opioid 
systems as atropine, hyoscine and other anticholinergics are e ffe c tive  
antagonists (B ill et al., 1983; Harris e t al., 1969; Leslie, 1969; Ireson, 1970; 
Paalzow and Paalzow, 1973; Wong and Bentley, 1979; Lewis et al., 1983) as 
are naloxone, naltrexone and benzomorphans (Harris et al., 1969; B a rto lin i e t 
al., 1979; Ben-Sreti and Sewell, 1982; Lewis et al., 1983). I t  is possible tha t 
catacholamines may also be involved as Pleuvrey and Tobias (1971) reported 
potentia tion by treatm ents which lower noradrenaline. Slater (1981) 
however, reports that neuronal lesioning w ith  6-hydroxydopamine, which 
destroys catecholam inergic neurons, acts through the noradrenergic system 
to antagonize oxotrem orine’s e ffe c t. Other reports also indicate a role fo r 
noradrenaline in the mediation o f oxotremorines antinociceptive actions 
(Sethy et al., 1971; Barar and Madan, 1976). Oxotremorine is believed to be 
the active m etabolite o f the compound trem orine (Cho et al., 1961), and 
trem orine itse lf has been shown to be antinociceptive in mice (van Eick and 
Bock, 1971; Lenke, 1938).
A recent study using stereospecific opioid antagonists has yielded im portan t 
im form ation on the mode of action of oxotremorine (Ben-Sreti and Sewell, 
1982). They report a reciprocal stereospecific sensitiv ity  fo r oxotrem orine
and opioid analgesics toward opioid antagonists. The (-)benzomorphan 
isomers, M rl452 and Mr2266, antagonized opioid induced antinociception but 
had no e ffe c t on oxotremorine-induced antinociception. Conversely the 
(+)benzomorphans, M rl453 and Mr2267 antagonized oxotremorine but not 
opioid antinociception. Furtherm ore (+)benzomorphans antagonized 
oxotremorine antinociception, but not tremorogenic or hypotherm ic actions 
(Ben-Sreti et al, 1982), suggesting muscarinic receptor subpopulations 
mediating these physiological e ffects, Koehn et al (1980) have shown the 
e ffec ts  of (+) and (-) opioid antagonists on DFP antinociception in the ra t to 
be opposite to tha t observed by Ben-Sreti and Sewell (1982) in m ice. This 
species d ifference may be due to the involvement, only in the mouse, o f 
noradrenaline in oxotremorine's antinociceptive action. A lte rn a tive ly , DFP 
may. act through the endogenous opioid system (Koehn et al 1980) w h ils t 
oxotremorine may not as i t  is re frac to ry  to (-)benzomorphan antagonism 
(Bensreti and Sewell, 1982).
Other muscarinic agonists, arecoline, RS 86, and pilocarpine have also been 
reported to be antinociceptive in a number o f species and tests, though 
potentia tion o f opioids has only been reported fo r pilocarpine (Knoll and 
Komlos, 1952; Wong and Bentley, 1979) and this e ffe c t is not universal 
(Kaakkola and Ahtee, 1977; Malec and Langwinski, 1982). An im portant 
exception in the antinociceptive a c tiv ity  of these muscarinic agonists is in 
studies in non-human primates. Using the rhesus monkey, Pert (1975) fa iled 
to show any antinociception fo r arecoline or pilocarpine. S im ila rly  the 
nociceptive response of the squirrel monkey was unaffected by pilocarpine 
(Houser and Houser, 1973). This does not appear to be due to the nociceptive 
test employed (e lec tric  shock titra tio n ), since pilocarpine has been shown to 
be active in e lectro foo t shock in rats (Houser and van H art, 1973; Kaakkola
and Ahtee, 1977) and arecoline was e ffe c tive  in ta il e lec trica l s tim ula tion 
(Metys et al., 1969). In addition, arecoline has antinociceptive a c tiv ity , as 
observed fo llow ing e lec trica l s tim ula tion of rabb it tooth pulp (Metys et al., 
1969). The d iffe ring  results, therefore, lie  in species differences. Pert (1975) 
suggests tha t the responses o f rodents may involve polysynaptic spinal 
reflexes which may be sensitive to cholinergic agents. A lte rn a tive ly  the 
neurochemical coding o f pain may be d iffe ren t in primates. These results 
indicate the possible p itfa lls  when extrapolating data obtained in rodents to 
primates, including humans.
b) N ico tin ic  Agonists
In the preceding sections most o f the papers describing antinociceptive 
actions of cholinom im etics and the e ffects  o f antagonists, have indicated 
tha t cholinom im etics exert the ir action through CNS muscarinic receptors. 
Indeed, the use o f n ico tin ic  antagonists has been shown to be in e ffec tive  in 
antagonizing cholinergic-induced antinociception (Pedigo et al., 1975; Dewey 
et al., 1975). However, there have been some reports describing potent 
antinociceptive actions o f nicotine and dimethylphenylpiperazine. N icotine 
has been shown to be antinociceptive in m ice, rats and dogs using a va rie ty  o f 
nociceptive stim u li. I t  is very rapid ly acting, exerting an e ffe c t 30 seconds 
a fte r s.c. adm in istra tion (T ripa th i et al., 1982). I t  appears to be acting only 
through n ico tin ic  receptors as atopine and hyoscine were in e ffec tive  in 
antagonizing nicotines antinociceptive e ffe c t, (Phan et al., 1973; T ripa th i et 
al., 1982), w h ils t mecamylamine was e ffe c tive  (Phan et al., 1973; Sahley and 
Berntson, 1979; T ripa th i e t al., 1982). However, Sahley and Berntson (1979) 
observed that hyoscine did antagonise nicotine and proposed tha t nicotines 
antinociceptive a c tiv ity  was mediated via release o f acetylcholine (see 
Section 1.6.6.(c)).
Species differences in nicotines action have been observed. Very close 
corre lations between nicotine brain levels and antinociception is seen in the 
mouse, but there is a poor corre lation in the ra t (T ripath i et al., 1982). 
Further studies indicated tha t th is finding is probably mainly due to the rapid 
development o f tachyphylaxis only in the ra t. This same group also observed 
tha t naloxone had very l i t t le  e ffe c t in the ra t, producing a maximum o f 23% 
inh ib ition of nicotine induced analgesia at a high dose o f 10 mg/kg. In mice, 
however, naloxone was e ffe c tive  from  0.1 mg/kg, though complete 
anatagonism could not be obtained. Sahley and Berntson (1979) also showed 
tha t naloxone was ine ffec tive  in the ra t.
The specific ganglionic stim ulant, dimethylphenylpiperazine has been shown 
to be antinociceptive in mice (Phan et al., 1973) and this appears to be a 
n ico tin ic  e ffe c t as mecamylamine is an e ffe c tive  antagonist.
These data, therefore, indicate that stim ulation o f the n ico tin ic  receptor in 
the CNS produces potent antinociception and on a molar basis equivalent to 
morphine (T ripath i et al., 1982). Again species differences are apparent as in 
the mouse nicotine’s action has an opioid component and does not exh ib it 
tolerance. In the ra t, antinociception is mediated through the n ico tin ic  
receptor and rapid tolerance occurs.
c) Choline Esters
The in traven tricu la r adm in istration o f acetylcholine has been shown to induce 
antinociception in mice. This e ffe c t can be blocked w ith  atropine, though not 
w ith  the quaternary derivative atropine m ethy ln itra te  or the n ico tin ic  
antagonist mecamylamine, indicating tha t acetylcholine exerts its
antinociceptive e ffe c t through centra l muscarinic receptors (Pedigo e t al., 
1975). Acetylcholine has also been reported to inh ib it morphine 
antinociception (M udgill et al., 1974). However, the e ffe c t is small and 
occurs 30 minutes a fte r i.c.v. in jection. As peak antinociception o f 
acetylcholine occurs around 10 minutes post in jection, its  antagonist e ffe c t 
on morphine antinociception probably acts through a mechanism d is tinc t from  
its  antinocicpetive e ffe c t. There is also evidence tha t a component o f 
acetylcholine's antinociceptive action is via opioid receptors. Its 
antinociceptive actions are antagonised by naloxone (Pedigo e t al., 1975; 
Pedigo and Dewey, 1981) and the rank order o f potency o f five  narco tic  
antagonists is the same fo r both acetylcholine and morphine (Pedigo e t al., 
1975). Furtherm ore, the divalent ions Mg^+, Mn^+ and Ca^+ but not Sr^+ or 
Ba^+ also inh ib it both acetylcholine (Widman et al., 1978) and morphine 
(Harris et al., 1977) antinociception.
I t  has also been reported tha t i.c.v. adm in istration o f 40 pg acetylcholine 
d iffe re n tia lly  altered the level o f four peptide and non-peptide brain 
fractions which had opio id-like a c tiv ity  (Chan et al., 1982). I t  is possible tha t 
these opio id-like m ateria ls mediate the antinociceptive e ffe c t o f 
acetylcholine.
There are, however, indications tha t acetylcholine exerts its antinociceptive 
e ffe c t through mechanisms d is tinct from  that fo r morphine. For example, 
Pedigo et a i. (1975) found that the 1-isomers o f pentazocine and cyclazocine 
blocked morphine w h ils t the d-isomers were w ithout e ffe c t; the converse is 
true fo r acetylcholine. Pedigo and Dewey (1981) have observed this reverse 
stereose lectiv ity w ith  the (+) and (-) isomers o f naloxone (cf. oxotremorine).
In addition, studies w ith  naloxone have yielded d iffe ren t apparent pA2 values 
fo r naloxone versus morphine and acetylcholine (6.86 and 6.09 respectively) 
and d iffe re n t slopes on the Schild p lot (-0.944 fo r morphine, -1.46 fo r 
acetylcholine) (Pedigo and Dewey, 1981). These marked differences indicate 
tha t naloxone inh ib its acetylcholine-induced antinociception non- 
com petatively. They also showed tha t there is an assym etrical cross 
tolerance between morphine and acetylcholine. The rapid tolerance to the 
antinociceptive e ffe c t o f acetylcholine only s ligh tly  decreased morphine 
antinociception, however, tolerance to morphine produced a 12-fo ld  increase 
in the ED^g of acetylcholine.
W ith respect to in te raction  and involvement o f amine systems, though 
reserpine and tetrabenazine pretreatm ent appeared to inh ib it acetylcholine 
antinociception, these compounds lack spec ific ity , and more specific  
depletors o f dopamine, noradrenaline or 5-HT were w ithout e ffe c t (Pedigo 
and Dewey, 1981).
In summary, the evidence indicates tha t acetylcholine exerts its  
antinociceptive through muscarinic receptors (Dewey et al., 1975) and tha t 
the mediation is independent o f opioid pathways.
Choline adm inistration has been shown to increase brain turnover and levels 
of acetylcholine (Cohen and Wurtman, 1975). Knoll and Komlos (1952) found 
tha t choline appeared to potentia te morphine antinociception. However, the 
dose o f 200 mg/kg used is probably tox ic. A t this dose o f choline morphine 
LD^g is reduced from  705 mg/kg to 66 mg/kg (Ho et al., 1979). A 
non-specific behavioural depression may therefore be responsible fo r an 
increased hot-p la te latency. The opposite e ffe c t o f choline was observed by 
B o ttic e lli et al. (1972) who found a dose-dependent attenuation o f morphine
antinociception using 30 and 60 mg/kg. A t 60 mg/kg, choline alone did not 
a ffe c t nociception. The authors Concluded tha t morphine's action may be due 
to its a b ility  to decrease acetylcholine release (Jhamandas ^ t  al., 1971) and 
so choline, which has been shown to increase acetylcholine levels (Cohen and 
Wurtman, 1975) may therefore attenuate the antinociceptive e ffec ts  of 
morphine. This hypothesis however, is not easy to reconcile w ith  the
lite ra tu re  concerning i.c.v. adm in istration o f acetylcholine (vide supra) and 
the lite ra tu re  concerning the e ffects  o f opioid analgesics on brain
acetycholine levels is contrad ictory (see Dewey et al., 1976). I t  is possible 
tha t choline may be acting on the post-synaptic cholinergic receptor; th is has
been proposed by Fredrickson and Pinsky (1975).
Carbachol does not cross the blood-brain barrier but several studies using 
i.c.v. and in tracerebra l (i.e.) adm in istration have demonstrated 
antinociceptive a c tiv ity  o f carbachol. Furtherm ore, i.e. application studies 
have gone someway in identify ing  the particu la r groups o f cells w ith in  the 
brain tha t are responsive to carbachol. Metys et al, co-workers (1969) 
showed tha t i.c.v. carbachol (at 1.25 gg) was antinociceptive in both ra t and 
rabb it. Local i.e. application indicated tha t the septal areas and m idbrain 
re ticu la r form ation - centra l grey region were both sensitive to 0.3 gg 
carbachol, whereas cudate putamen and dosal hippocampal adm in istra tion 
only showed effects  between 5 and 10 gg, doses at which transventricu la r 
d iffusion may w e ll occur.
Brodie and P roud fit (1984) examined the role o f the cholinergic system on the 
nucleus raphe magnus (NRM). This structure in the caudal medulla has been 
shown to a ffe c t nociceptive processing (see Fields and Basbaum, 1978), and 
also to possess cholinergic term inal markers. For example, cholinerg ic
receptors (Kobayashi et al., 1978) acetylcholinesterase (Palkovitz and
Jacobowitz, 1974) and choline acetyltransferase (Kobayashi et al., 1975). 
Brodie and P roud fit (1984) showed that carbachol (i.e.) produced 
antinociceptive responses, which could be reversed by atropine or prevented 
by atropine pre trea tm ent. The authors suggest that carbachol acts on the 
NRM to activa te  descending raphe-spinal neurons, which impinge on spinal 
cord dosal horn neurons. It  is these neurons which are sensitive to noxious 
s tim ulation (see Brodie and P roud fit, 1984 fo r references).
In the cat, Katayama et al. (1984a,b) found a group o f cells in the 
parabrachial region (PBR) very sensitive to the antinociceptive e ffec ts  o f 
carbachol. This appears to be solely a muscarinic response as i t  is inhib ited 
by atropine, but not mecamylamine or naloxone. Morphine at a dose o f 25 gg 
had no e ffe c t when in jected into the same site . Although a role fo r these 
groups of cells which appear to mediate nociceptive in form ation via 
muscarinic receptors is not clear, i t  is possible that they are the substrate fo r 
environm entally induced antinociception. This form  of antinociception is 
discussed in Section 5.
1.6.7. Cholinergic Antagonists and Antinociception
The previous sections have described the lite ra tu re  concerning 
cholinom im etic agents and give a strong indication that antinociception is at 
least in part mediated by acetylcholine in the CNS. The use o f antagonists in 
nociceptive studies is shown in Table 4 and provides fu rthe r support fo r the. 
role of acetylcholine in nociception and opioid function.
Hemicholinium decreases acetylcholine levels in the cerebral cortex 
(Rodriguez de Lores Arnaiz et al., 1970), by in te rfe ring  w ith  choline transport
(Marchbanks, 1968) and pretreatm ent w ith  this compound s ligh tly  antagonises 
the antinociceptive action o f morphine (Bhargava et al., 1974). 
Hem icholinium  itse lf has no antinociceptive a c tiv ity . This would suggest tha t 
part o f morphine's action involves cholinergic neurones. Hem icholinium  has 
also been shown to inh ib it acupuncture antinociception fo llow ing i.c .v . 
adm in istra tion (Ren et al., 1980). The role o f the cholinergic system in 
acupuncture antinociception is discussed in Section 1.6.7.(b).
The muscarinic antagonist, hyoscine, administered by the peritoneal route is 
not antinociceptive in mice (B ill e t al., 1983) or rats (Houser and van H art, 
1973; B ill et a l., 1983; Lewis et a l., 1983) and indeed causes s ign ifican t 
hyperalgesia in ra t ta il f lic k  tests at 1 mg/kg (Watkins et al., 1984). 
However, s.c. adm in istration has been shown to produce potent 
antinociception using the mouse w rith ing  test, which may re fle c t route o f 
adm in istra tion or perhaps a peripheral in teraction w ith  the w rith ing  agent 
phenylbenzoquinone.
Data from  prim ate studies (Houser and Houser, 1973; Pert, 1975) indicate 
tha t hyoscine is antinociceptive at low doses. Though con flic ting  w ith  the 
rodent data these results are consistant w ith  the findings described in 
Section 1.6.6.(a), on the study o f muscarinic agonists in primates, indicating 
again tha t pain pathways may be species dependent. When hyosine was 
administered into discreet brain regions that had been shown to be responsive 
to morphine, no antinociception was observed. Ventricu la rly  administered 
hyoscine was e ffe c tive  however, thus strongly suggesting a cholinerg ic 
pathway tha t modulates nociception at least in part d is tinct from  opioid 
sensitive systems (Pert and Maxey, 1975).
Opioid induced antinociception has been shown to be inhib ited in two species 
by hyoscine (B ili et al., 1983) though not in the w rith ing  test, but this could 
be re lated to hyoscine's own antinociceptive a c tiv ity  in this test. Malec and 
Langwinski (1982) found tha t hyosine enhanced codeine's effectiveness whilst 
leaving morphine, fentanyl and pentazocine unaffected.
The use o f cholinergic antagonists has indicated possible transm itte r 
substrates fo r endogenous environm entally induced antinociception. 
Endogenous antinociception may be induced by stressful s tim u li, such as cold 
water swimming (Bodnar et al., 1978), e lec tric  shocks (Jackson, 1979), and 
figh ting  (Rodgers and Hendrie, 1983). In many cases the antinociception is 
naloxone reversible im plying a role fo r endogenous opioid systems. However, 
some forms of environm entally induced antinociception are re frac to ry  to 
narcotic antagonists, fo r example b rie f continuous, as opposed to prolonged 
in te rm itta n t, foo t shock (Lewis et al., 1980), and hind paw, as opposed to 
fro n t paw, foo t shock (Watkins and Mayer, 1982) appear to u tilize  non-opioid 
mechanisms. The cholinergic system has been im plicated by some workers in 
environm entally induced antinociception, as hind paw foo t shock induced 
antinociception and antinociception induced by classical conditioning are 
blocked by hyosine (1 mg/kg), but not the quaternary deriva tive , 
methylhyoscine (Watkins et al., 1984). Prolonged in te rm itta n t shock was dose 
dependently antagonised by hyoscine from  0.1 mg/kg (Lewis e t al., 1983), 
s im ila rly  long term  opioid antinociception induced by inescapable foo t shock 
followed by m ild re instating shocks 24 hours la te r was also antagonized by 
hyoscine at 2.5 mg/kg. The indications are tha t some form s of 
environm entally induced antinociception are mediated via centra l muscarinic 
system, whilst others act through endogenous opioid systems which employ 
in term ediary muscarinic cholinergic pathways.
1.6.8 Miscellaneous Compounds
The role of the cholinergic system in nociception has been im plicated by 
pharmacological treatm ents not d irec tly  involving the use o f cholinergic 
drugs. There are several neurotransm itters which have been reported to be 
involved in nociception, one o f which is the inh ib ito ry  amino acid 
Y -am inobutyric acid (GABA). The role o f GABA as an analgesic has been 
suggested from  studies w ith  an analogue, baclofen (Saelens et al., 1980). The 
lack o f antagonism by naloxone indicates that baclofen acts through an 
opioid-independent system.
Kendall et al. (1982) investigated the role o f GABA in nociception using 
d irec tly  acting agonist (kojic amine and THIP), a GABA-degradation inh ib ito r 
(y-v iny lG A B A ) and an inh ib ito r o f high a ff in ity  transport (n ipecotic acid 
e thyl ester). As w ith  previous studies, naloxone (5 mg/kg) fa iled to a lte r the 
antinociceptive a c tiv ity  o f these compounds in mice using hot plate and ta il 
immersion tests. In contrast atropine (5 mg/kg) inhib ited the antinociceptive 
a c tiv ity  of a ll treatm ents w hilst mecamylamine (5 mg/kg) was in e ffec tive . 
Those drugs which m odify GABAergic transmission probably do not exert 
the ir e ffe c t by acting d irec tly  on muscarinic receptors as only n ipecotic acid 
showed sign ificant a ff in ity  fo r the receptor in binding studies. The results 
indicate then, that GABA is exerting its  antinociceptive e ffe c t via 
in term ediary cholinergic neurons.
2+ 2 
The divalent cations barium (Ba +) and strontium  (Sr +) are believed to be
able to substitute fo r calcium ions to induce release o f neurotransmitter.s
2+(Rubin, 1970) and Ba has been shown to release acetylcholine (Silinsky,
1977). Using the mouse ta il- f l ic k  model Welch et al. (1983) demonstrated
2+ 2+that in traven tricu la r administered Ba and Sr induced antinociception.
This e ffe c t was reversed by atropine but naloxone antagonism was not dose
2 2+related. These results suggest that Ba +'s and Sr +,s inherent antinociceptive 
a c tiv ity  is mediated via acetylcholine release.
The involvement o f the cholinergic system in antinociception may be o f 
c lin ica l significance w ith  the recent development o f the analgesic drug 
meptazinol. This drug appears to possess both opioid and cholinerg ic 
antinociceptive components as B ill e t al. (1983) demonstrated in several 
rodent antinociceptive tests (see Table 1.4.) that m eptazinol’s e ffec ts  were 
inhib ited by naloxone, atropine and hysocine. It  has been reported recently  
that meptazinol possesses cholinergic a c tiv ity  by v irtue  o f its  marked 
anticholinesterase a c tiv ity  (G alli, 1983). The possibility o f u tilis ing  the 
cholinergic component c lin ica lly  is o f great in terest as the drug seeking 
behaviour and addictive lia b ility  o f cholinergic or opio id-cholinergic 
analgesics may be less than that observed w ith  opioids.
1.6.9 Acetylcholine Histopharmacology and Opioids
a) Role o f Acetylcholine in Nociceptive Pathways
The previous sections have described how the cholinergic system is involved 
in nociceptive processing. The question arises as to whether there is an 
anatom ical corre late of these pharmacological observations.
Morphine has been shown to inh ib it acetylcholine release from  the guinea-pig 
ileum (Paton, 1957; Schaumann, 1957) and to increase levels in the brain (e.g. 
Herken et al., 1957). These studies demonstrating morphine action in 
increasing brain acetylcholine levels was observed only at doses above tha t 
required fo r antinociception. However, these were measurements in whole 
brain, and more recent studies have measured regional changes in
acetylcholine, w ith  antinociceptive doses. Green et al. (1976) showed tha t in 
mice, 10 mg/kg morphine increased acetylcholine levels s ign ifican tly  in the 
stria tum  and at higher doses (300 mg/kg) in the hippocampus. In rats 
increases in s tria ta l acetylcholine was observed a fte r 30 mg/kg, and a fte r 
90 mg/kg increased levels were measured in the hippocampus; these e ffec ts  
were shown to be naloxone reversible. There is m v itro  evidence tha t this 
e ffe c t is due to morphine's action on h ig h -a ffin ity  Na+-dependent choline 
transport (HANDCU), an ind ica tor o f cholinergic neuronal a c tiv ity  m vivo 
(Kuhar and M urrin, 1978). I t  has been shown tha t at antinociceptive doses 
morphine stim ulates HANDCU in mouse s tria ta l (Vallano et al., 1982) and ra t 
hippocampal (Vallano and McIntosh, 1980) synaptosomes. In addition, 
enkephalin at 40 nM was shown to decrease neocortical HANDCU (Wenk,
1984). I t  is also possible tha t opioids increase acetylcholine levels by 
inh ib iting  its  release, i.e. decreasing cholinergic neuronal a c tiv ity . Indeed, 
release o f co rtica l acetylcholine may be evoked by e lec trica l s tim u la tion  o f 
nerves in the forepaw o f anaesthetized rats (Jhamandas and Sutak, 1983) and 
this is enhanced fo llow ing systemic adm in istration o f the narcotic antagonists 
naloxone or naltrexone. This suggests tha t there is an inh ib ito ry  ro le fo r 
endogenous opioids on acetylcholine release. Opioid receptor regulation 
appears to be lim ite d  to certa in pathways (Wood et al., 1984) viz, septal- 
hippocampal and substantia innom inata-cortica l pathways where agonists a t 
p, 6 and e receptors exert inh ib ito ry  regulatory influences, w h ils t k-agonists 
appear to be ine ffec tive . In addition, there is a co-loca liza tion o f enkephalin 
and acetylcholine in the la te ra l system of olivocochlear cells (A ltschu ler et 
al., 1983) and several preganglionic parasympathetic neurons (Glazer and 
Basbaum, 1980).
This co-existence, and possibly co-release, may also occur in other neuronal 
systems, and the lite ra tu re  describing the relationship between opioid and 
acetylcholine turnover and release suggest a close relationship between these 
two systems. I t  is quite plausible, tha t acetylcholine plays a key ro le in the 
actions o f endogenous and exogenous analgesia.
b) Acetylcholine and Acupuncture-Induced Antinociception
In China, acupuncture is used routine ly as a method to induce surgical 
analgesia. The mechanism of this e ffe c t is s t il l poorly understood. I t  is only 
in recent years tha t th is technique has, at least in the West, received any 
credence and undergone sc ie n tific  enquiry. The possible mechanisms involved 
\d  acupuncture-induced analgesia have been reviewed recently (Han and 
Terenius, 1982). There are several reports describing the role o f the 
cholinergic system in acupuncture antinociception. Acupuncture causes an 
increase in acetylcholine in the CSF and the increase correlates w ith  increase 
analgesia (He et al., 1979). In rats, acetylcholine levels were found to 
increase during electroacupuncture-induced antinociception in the locus 
coeruleus and dorsal raphe (Ge, 1979) hypothalamus and nucleus caudatus 
(Wang et al., 1979). In addition, increased acetylcholinesterase a c tiv ity  was 
observed in the thalamus fo llow ing electroacupuncture and locus coeruleus 
though a c tiv ity  was reduced in the substantia gelatinosa (A i et al., 1979).
Pharmacological manipulation of the cholinergic system has added to the 
evidence fo r a role o f acetylcholine in acupuncture-antinociception. 
Inh ib ition o f acetylcholine synthesis w ith  hemicholinium (i.c.v.) was shown to 
inh ib it electroacupuncture in rats (Han, 1979; Guan, 1979), and this could 
pa rtia lly  be reversed w ith  the acetylcholine precursor choline chloride (Han, 
1979). Blockade of muscarinic receptors w ith  atropine in rats and rabbits
(Han, 1979) and w ith  hyoscine in rabbits (He et al., 1979) was found to block 
analgesia induced by acupuncture, w h ils t the anticholinesterase 
physostigmine has been shown to potentia te acupuncture analgesia in rats 
(Han, 1979; G u a n e ta l., 1979; A i, 1979).
There is also evidence fo r the involvement o f other transm itte r systems (e.g. 
endogenous opioid and 5-HT) suggesting a m ultip le  neurtransm itter system 
mediating the e ffec ts  o f acupuncture (See, Han and Terenius, 1982, fo r 
review).
c) Acetylcholine-Q pio id In te raction  in Non-Nociceptive Systems
There are a number o f reports in the lite ra tu re  describing in teractions 
between centra l cholinergic and opioid systems not involved in nociception, 
but having potentia l c lin ica l applications. For example, anaesthesia has been 
shown to be potentiated or prolonged fo llow ing anticholinesterases (Pellanda, 
1933; Green and Davis, 1956). Another potentia l benefic ia l e ffe c t o f the 
opioid-cholinergic in teraction has been investigated by Weinstock and her 
colleagues. The respiratory depressant e ffe c t o f morphine, or other opioids 
tha t are routine ly given as part of pre-operative medication is usually not 
im portant, however, in patients w ith  lung diseases or breathing problems such 
an e ffe c t is po ten tia lly  fa ta l. However, physostigmine pretreatm ent has been 
shown to antagonize respiratory depression in experimental animals 
(Weinstock et al., 1980) and humans (Snir-Mor et a l., 1983). This property o f 
physostigmine has been exploited successfully in the trea tm ent o f severe 
resp ira tory depression resulting from  overdose in heroin addicts (Rupreht et 
al., 1984). The authors point out tha t physostigmine trea tm ent is preferable 
to the usual procedure of adm in istration o f naloxone, as acute w ithdraw al is 
not precip ita ted.
Treatm ent of opioid addiction is an im portant area of research in opioid 
pharmacology, and there is evidence that the cholinergic system modulates 
the processes of tolerance and dependence to opioids. The lite ra tu re  has 
been extensively reviewed (Wahlstrbm, 1978); short-term  morphine 
trea tm ent ( 3 days) appear to increase acetylcholine turnover in it ia lly  
(Bhargava and Way, 1975; Cheney et al., 1975), w h ilst several studies indicate 
that longer treatm ent (2-4 weeks) appears to result in increase levels or 
decreased acetylcholine u tiliza tio n  (e.g. Domino and Wilson, 1973). A 
possible c lin ica l application to the use o f a cholinergic drug in the trea tm ent 
o f dependence and w ithdrawal has been proposed by Albin et al. (1975). They 
reported that nalorphine-precipitated w ithdrawal signs fo llow ing constant 
morphine plus an anticholinesterase (tetrahydroam inoacridine, THA) dosing in 
rhesus monkeys were markedly less than that observed a fte r morphine alone 
treatm ent. Indeed, an earlie r study indicates that THA adm in istra tion 
reduces physical dependence in humans (Stone et al., 1961).
There is evidence fo r a cholinergic involvement in a ffec tive  disorders (e.g. 
depression) in humans, as fo llow ing adm inistration o f physostigmine in normal 
subjects resulting symptoms include many o f those.associated w ith  depressive 
symptomatology (Risch et al., 1980). In addition, in patients w ith  a h istory o f 
a ffe c tive  disorder, but w ith  c lin ica l remission, infusion o f low doses o f 
physostigmine produces transient depressive symptomatology (Janowsky et 
al., 1974). More recent studies (Risch e t al., 1981) have shown tha t 
adm inistration of physostigmine or ajrecoline to both normal and a ffe c tiv e - 
disorder subjects produces altered mood and a ffe c tive  changes, resulting in 
increased depression. These observed e ffects  were highly corre lated w ith  
increased plasma 3-endorphin im m unoreactiv ity (but not co rtiso l or 
pro lactin) and the authors suggest the existence o f a cholinerg ically mediated 
3-endorphin pathway modulating a ffec tive  and cognitive states in humans.
A classical response to opioid adm inistration in mice is to increase the ir 
locomotor a c tiv ity . This stereotypic running is believed to be dependent on 
dopamine (Kushinsky and Hornykiew icz, 1974; Eidelberg and Erspamer, 
1975), but there is also evidence that a component o f morphine's action 
involves the cholinergic system. Adm inistra tion of the muscarinic receptor 
agonist oxotremonine (Seidel et a l., 1979), or the anticholinesterase agent, 
DFP (Su and Loh, 1975), attenuate morphines e ffe c t on locomotion, w h ils t the 
muscarinic antagonist, atropine enhances morphines action (Seidel e t al., 
1979). Cholinergic drugs appear then to influence opioid-induced running. 
The mechanism is unclear, but may w e ll involve other neurochemicals, such 
as catecholamines.
1.6.10. Conclusions
Several agents which in te rfe re  w ith  the cholinergic system have been shown 
to be antinociceptive. These include reversible and irreversib le  
anticholinesterases and agonists at muscarinic and n ico tin ic  receptors. To 
a ffirm  that cholinergic drugs potentia te the analgesic action o f opioids is 
perhaps an overgeneralisation. However many experimental studies have 
been able to show that enhancement o f cholinergic a c tiv ity  can lead to 
enhancement o f opioid antinociception. In addition there is evidence to 
suggest that endogenous analgesia, induced by stress may in part be 
modulated by cholinergic inputs.
The in teractions between the cholinergic and opioid systems probably 
prim arily  occurs w ith in  the centra l nervous system as studies w ith  quaternary 
compounds have been mostly negative whilst in teractions fo llow ing centra l
adm inistration are generally observed. The molecular mechanisms involved 
are not understood but most o f the evidence points to a pharmacodynamic 
rather than a pharmacokinetic in teraction.
Too few studies have used receptor selective antagonists and where 
cholinergic antinociception has been observed the involvement o f both 
cholinergic and opioid receptors is often the case. Our understanding o f 
in teractions at the receptor level require more selective pharmacological 
tools espeically w ith  respect to opioid pharmacodynamics. I t  is also probably 
an overs im plifica tion to th ink o f an opio id/cholineric in te raction  involving 
only one mechanism and there may be in terrelationships w ith  other neuronal 
systems. In particu la r the evidence points to a close relationship w ith  
monamines. Whether manipulation o f cholinergic and opioid system produces 
more successful pharmacological agents are analgesics remains to be seen.
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CHAPTER 2
Antinociceptive Activity of Morphine, Fentanyl and Alfentanil
in Mice and Rats:
Effect of DFP and Drugs Used in the Treatment of DFP Poisoning
INTRODUCTION
2.1. An tinoc icep tive  Models
There are many tests available to determ ine the antinociceptive a c tiv ity  of 
drugs. The m a jo rity  o f these tests u tilize  the response to experim ental pain 
in animals (Linebery, 1981). Anim al testing can only serve as a model of 
human c lin ica l pain as the pain response in man is a subjective param eter 
w ith  large va riab ility  between individuals. Extrapolation from  animal data to 
humans must be viewed w ith  caution as false negatives and positives may be 
encountered.
Wood (1984) presented a lis t o f five  c r ite r ia  fo r consideration when 
in te rpre ting  data from  animal screening tests:
1 Test V a lid ity : Is the test predictive o f the c lin ica l u t i l i ty  o f known
analgesics?
In considering the most appropriate antinociceptive test in this 
study, these points were taken in to consideration. I t  was decided to 
employ the hot-p la te test (Woolfe and MacDonald, 1944) fo r mice 
and the paw pressure test (Randall and Se litto , 1957) fo r rats.
2 Test R e lia b ility : Is the test response reproducible throughout an
experimental day and from  day to day?
3 Test S im p lic ity : Does the procedure use a standard defined noxious
stimulus, measure a well-defined animal response, and is the test 
easily utilized?
The mouse hot-p la te is an extensively used procedure and unlike the 
ta il f lic k  test does not re ly on a re flex ive  response. The paw lick  
response in the hot-p la te test relies on integrated behaviour 
involving processes occuring at a high level w ith in  the centra l 
nervous system. The ra t paw pressure test was chosen to determ ine 
antinociceptive drug a c tiv itie s  in an additional species using a 
d iffe re n t noxious stimulus, and in this test the responses are not 
re flex ive  in nature.
An tinociceptive  responses are subject to wide variations, so care 
was taken to account fo r and contro l environmental variables.
Test S ensitiv ity : Can d iffe ren t analgesic doses be discrim inated and 
can the procedure detect weak and agonist/antagonist analgesics?
The paw pressure test, but not the mouse hot-p la te  test is sensitive 
to agonist/antagonist analgesics. In th is study, this would not be so 
im portant as only strong analgesics were investigated.
Data Analysis: Varies between laboratories. Is the method of
analysis appropriate? Methods o f analysis should be described.
The analysis o f the data was given fu ll consideration, and a model 
was developed to accurately f i t  the form  of the observed data (see 
Section 2.10.).
2.2. In it ia l Experiments
Ample evidence has been presented in Section 1.6. fo r the role of cholinergic 
agents in opioid antinociception. The in it ia l studies, which are presented in 
this section, were designed to determ ine the in teractions between the 
anticholinesterase agents and opioid antinociception in the models described 
above.
MATERIALS AND METHODS
2.3. Anim als and Experim ental Conditions
Male albino mice (CD-I strain; 25-30g) were purchased from  Charles R iver. 
Male albino Wistar rats (Surrey U nivers ity  strain; 140-210g) were bred at the 
University 's Anim al U n it. Upon delivery, animals were housed in the Anim al 
U n it under contro lled temperature, hum id ity and lighting conditions (12h 
ligh t/da rk  cycle; lights on 0700h). Mice remained in the U n it fo r at least 5 
days before use. Tw enty-four hours before experimentation, the animals 
were equilibrated in a quiet laboratory where a ll procedures were carried out. 
Animals had free access to food and water up to experim entation. A ll 
experiments were carried out between 0900h and 1300h.
The quiet laboratory (3.3m x 3.5m x 2.75m high) was windowless and had the 
same lighting conditions as the Anim al U n it. The room was ventila ted but 
had no independent heating or hum id ity controls. Am bient tem perature was 
monitored during experimentation, and stayed w ith in  the range 20-25°C 
throughout the year. So as to minimise disturbance there was res tric ted  
access to the room before and during experimental procedures.
2.4. Drugs
The fo llow ing drugs were used:
DRUG NAME SOURCE
Di-isopropylfluorophosphate Sigma
A tropine sulphate Sigma
Morphine sulphate M acfarlan Smith
Fentanyl c itra te Janssen Pharm aceutical*
A lfe n ta n il hydrochloride Janssen Pharm aceutical*
Pralidoxim e m ethyl sulphonate CDE, Porton Down*
Diazepam Roche*
Neostigmine bromide Sigma
Pyridostigm ine bromide Roche*
Naloxone hydrochloride Endo*
*  These compounds were generously donated by the manufacturers.
Drugs were dissolved in 0.9% saline (Travenol) im m ediate ly prior to use, w ith  
the fo llow ing exceptions: in some experiments DFP was dissolved in peanut 
o il (Sigma), and as diazepam is not soluble in saline i t  was f irs t dissolved in 
polyethylene glycol 200 (PEG) to which an equal volume of saline was added 
to give the correct drug concentration. Great care was taken in handling 
DFP due to its highly tox ic  nature. The supplied Safety Data Sheet was used 
as a guideline to handling procedures outlined below:
2.5. Safety Procedures fo r  DFP
DFP was stored, re frige ra ted  at about 4°C, and kept w ith in  the lidded m eta l 
container in which i t  was supplied. The v ia l containing DFP was handled only 
in a fume cupboard, w ith  the user wearing gloves and an overall w ith  tig h t 
cuffs.
Appropriate quantities o f DFP were obtained by penetrating the seal w ith  a 
fixed needle Ham ilton syringe and w ithdrawing liquid. The DFP was 
im m ediate ly transfered to a vo lum etric flask to which saline was added. The 
flask was shaken thoroughly fo r at least 2 minutes to ensure tha t the DFP had 
dissolved. The fume cupboard also contained a bucket containing 2% sodium 
hydroxide. Any accidental spillages or contaminated equipment could be 
neutralised in copious quantities o f the sodium hydroxide solution.
DFP degrades w ith  tim e due to hydrolysis (Leopold and Krishna, 1963) and 
therefore stock was replaced every six months. In addition, a lfen tan il 
potentia ting a c tiv ity  was confirm ed (see Section 2.13.).
2.6. Dosing Protocols in M ice
Mice were scruffed and drugs were in jected in 0.1ml volumes subcutaneously 
(s.c.) in the back o f the neck, w ith  the exception o f diazepam and 
neostigmine. Diazepam was in jected in a 0.03ml volume in tram uscularly 
(i.m .) into the hind leg, because o f a local in teraction w ith  DFP (D. Green, 
CDE, personal communication), and neostigmine was in jected 
in traperitonea lly  (i.p.) in 0.1ml volumes.
Drug dosing protocols are illus tra ted  in Figure 2.1. When used, atropine 
(17mg/kg) and pralidoxime (15mg/kg) were mixed and in jected together 1 
minute a fte r DFP, according to Gordon et al (1978). Diazepam (6.25pm ol/kg) 
was in jected im m ediate ly prior to the atropine/pralidoxim e dose (D. Green, 
personal communication).
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For the neostigmine experiments, e ither saline or neostigmine were 
administered (i.p.) at tim e 0, a lfen tan il 25 minutes la te r, and antinociceptive 
testing carried out at 30 minutes.
Pyridostigm ine (lm g/kg) was administered 1 hour before antinociception. The 
times fo r the in jection o f morphine, fentanyl and a lfen tan il were 30, 50 and 
55 minutes a fte r pyridostigm ine, respectively.
In those experiments when naloxone was used, i t  was administered 30 minutes 
before testing.
2.7. Dosing Protocols in Rats
Rats were scruffed fo r s.c. in jection (0.1ml volumes) in the back o f the neck. 
DFP was administered at tim e 0 and morphine, fentanyl or a lfen tan il 
administered 30, 50 and 55 minutes la te r respectively. Each animal was 
tested four times; once im m ediate ly before the f irs t in jection and again at
three times to include peak antinociceptive e ffe c t. The tim ings fo r
\
in jections and fo r post-drug testings are given in Fig 2.2.
i_ m  
° 2  
Q— I
\k<Q  CO
I------
z
<
H-
LUh-H
LLC0C0 C0
—I LULU LU
< t-h - h-
a pCD O
CO
C
E
LU
— 11 l— f
lO N - O  10 
1 0 1 0 (0  CO
u-LLI
°2
Q___I
l l <
QCO
co
c
Ew
LU
>-
Z
<
K" h" H
ZC0 CO CO
LULU LU UJ
LL h- H
1 < 1
h-
o  m o O
m m cd N-
l-LU
° Z
0 ___I
U-<
QCO
LU
z
X
CL
Xo
co
c
E
LU
h-
O
H —
o
00
h-
CO
LU
I-
-+-
I-
CO
LU
H
—h-
I-
co
LU
I—
O
LO
O
CO
—l
o
O)
bO
£ CO ■H P 
P d CO P3 
0
EH £  
•H
co
<M
bD•H
TS 
£ d 
O 
bfl O
c o•H +->
0 o
O £ 
Q a
o•H
O
o
£•HP
d
d
0•n
£•H
COd
£
0
£•H
0 .£ 
£■ » £ 
O
>>-P >! 
•H 0 
> Si •H P 
Po n  d *h 
O
d a  
o o
O Oi- 1 *H 
£
Oo
d
S £ 
d
r£  P
a  £ 
0
O £  
0 
e. 
0 T3
CO 
0 rH •H
o 
£
a
0
a•H
-P
-P 
£0 «H 
£  «H 
0 -H
<H•H P 
d
T3
0PCO
0p
0
£
0
£
COpd
£
CO Ti •H
O•H ~
a p  o o 
00 «H X! <H 
E-f 0 30 
mi
nu
te
s 
af
te
r 
DF
P,
 
an
d 
an
im
al
s 
we
re
 
te
st
ed
 
20
, 
30 
an
d 
60 
mi
nu
te
s 
af
te
r 
re
ce
iv
in
g 
th
e 
op
io
id
. 
Fe
nt
an
yl
 
in
je
ct
ed
 
50 
mi
nu
te
s 
af
te
r 
DF
P 
an
d 
an
im
al
s 
te
st
ed
 
5,
 
10 
an
d 
20 
mi
nu
te
s 
la
te
r.
 
Al
fe
nt
an
il
 
wa
s 
a
d
m
in
is
te
re
d 
mi
nu
te
s 
af
te
r 
an
im
al
s 
re
ce
iv
ed
 
DF
P,
 
wi
th
 
an
ti
no
ci
ce
pt
iv
e 
te
st
in
g 
at 
2,
 
5 
an
d 
10 
mi
nu
te
s 
af
te
r 
al
fe
nt
an
il
.
2.8. Antinociceptive  Testing in Mice
The hot-p la te  test (Woolfe and MacDonald, 1944) was employed fo r 
antinociceptive testing. The hot plate was made in the Biochem istry 
workshop, University o f Surrey, and consisted o f an aluminium plate (30cm 
xl5cm) surrounded by a transparent perspex w a ll (22cm high). This was 
placed in a therm osta tica lly  contro lled w ater bath w ith  the water maintained 
at 33°C. The same apparatus and temperature setting was used throughout 
a ll experiments.
When tested mice were placed on the hot-p la te and a hand-held d ig ita l 
stopwatch started as soon as the mouse touched the plate, the nociceptive 
end-point was taken as paw-licking (in most cases this was the fore-paw) or 
jumping on the few occasions when the lick ing response was absent. I f  the 
mice fa iled to respond a fte r 60 seconds they were removed from  the plate 
and scored as >60 seconds. As the walls o f the hot-p la te were perspex and 
unheated, occasionally some mice spent long periods on the ir hind paws w ith  
fore-paws resting on the walls; these mice were excluded.
2.9. Antinociceptive  Testing in Rats
The non-inflamed paw pressure test was employed fo r nociceptive 
determ inations (Randall and Se litto , 1957) using an Ugo Basile Analgesy m eter 
(A .R .Horwell, London). This apparatus (Fig. 2.3. ) consists o f a p lastic pusher 
(P) positioned about 2mm above a Teflon p lin th  (B). Animals were held 
f irm ly , but not tig h tly  around the upper part o f the ir body, so they could be 
held in the correct position w ithout the animal struggling. The animals paw, 
was placed under the pusher and subjected to a force increasing linea rly  w ith  
tim e as a pivoted weight (W) moved horizonta lly. A foot-pedal contro lled the
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weight's movement which v/as marked o ff on a graduated scale (SC). The
score on the graduated scale was converted to the force applied in grams by
m ultip ly ing by 30.
The nociceptive end-point was taken as a w ithdrawal or attem pted 
w ithdrawal o f the animal's paw, or when the animal struggled. With practice 
i t  was possible^ distinguish between struggling in response to the noxious 
stimulus and non-specific struggling. Both hind paws, in turn, were placed 
under the pusher and a mean value taken as the score fo r tha t animal. To 
avoid damage to the animal's paws, a maximum c u t-o ff weight o f 750g was 
employed. Those animals which did not respond before the 750g c u t-o ff  was 
reached were scored as 750g.
2.10. S ta tis tica l Procedures
2.10.1. H ot-P late Data
Four doses fo r each opioid were used to obtain a dose-response curve. Each 
point was the mean of 12 or 18 observations made on 2 or 3 separate days. 
The dose-response relationship was represented by an AD^-g value, which was 
defined as the dose required to increase the hot-p la te  latency to 30 seconds 
(ie., 30% of the maximal response tim e). Unpaired Student's t- te s t (see 
Appendix A) was used to.compare AD<-g values.
A ll dose response curves included censored values, tha t is mice fa iling  to 
respond before the 60 seconds c u t-o ff, which were scored as >60 seconds. 
Though employing a c u t-o ff tim e is essential to avoid inducing tissue damage 
in the animal's paws, i t  does d is to rt the dose-response relationship. However, 
this d istortion may be compensated fo r by using appropriate m athem atical 
models. Such a model was applied to the data to obtain AD^g values and is 
described in Appendix B. The Fortran listings fo r the test procedures (run on 
the Prime computer operating system) are given in Appendix B.
2.10.2. Paw Pressure Data
A m athematical model was applied to data giving the tim e course of drug 
e ffe c t to obtain values fo r peak responses fo r each dose. Comparison 
between groups was by unpaired *t’ test. Results were norm ally mean values 
o f at least six animals. To obtain a value fo r peak response, a quadratic 
equation was f it te d  to the data: y = a - b (x-c) , where: a = peak response 
score, b = curvature o f line and c = tim e o f peak response
RESULTS
2.11. Pilot Studies
Repeated exposure to antinociceptive testing procedures of naive mice (ie., 
non-injected) was assessed on the hot plate (Table 2.1.). Re-testing the same 
mouse resulted in s ign ifican tly  increased latency. A ll subsequent 
antinociceptive data presented represent latencies from  mice tested once 
only.
Table 2.2. shows the e ffe c t of repeated saline in jection on nociceptive 
responses o f mice. There were s ign ificant changes (eg., single in jection  11.7 - 
0.73, tr ip le  in jection 9.2 - 0.85, t- te s t p<0.05), but these were quan tita tive ly  
small.
2.12. E ffect of DFP on Nociception in Mice
Table 2.3. shows tha t DFP at lm g/kg did not exh ib it antinociceptive a c tiv itie s  
a t the times studied. However, a t a 2mg/kg dose a 2- to 3-fo ld  increase in 
hot-p la te response tim e was observed over th is period. A t th is higher dose, 
mice exhibited symptoms of anticholinesterase poisoning, such as trem ors and 
fasiculations. Mice showed hind-limb abduction and impaired and reduced 
ambulation.
When peanut o il was used as the vehicle fo r DFP (Table 2.4.) no a lte ra tion  in 
hot-pla te response tim e was observed compared w ith  saline.
The e ffe c t o f the opioid antagonist, naloxone, and the muscarinic cholinerg ic 
antagonist, atropine, on the antinociceptive a c tiv ity  o f DFP at 2mg/kg is 
shown in Table 2.5.
Table 2.1. E ffect of Repeated Exposure to Antinociceptive Testing 
Procedures on Hot-Plate Times of Naive Mice
One exposure
Second exposure (+ 30 mins) 
Third exposure (+ 4 hours)
H ot-P la te  Latency (Secs)
9.3 - 2.0
17.0 - 3.3
16.8 i  2.0
Each value represents the mean - SEM of 12 observations.
Table 2.2. E ffect of Multiple Saline Injections on Hot-Plate Response Time in Mice
H ot-P la te  Latency (Secs)
Number o f Time from  last in jection to test
Injections
30 mins 10 mins 3 mins
1 11.7 - 0.7 (56) 10.3 - 1.1 (12) 9.6 - 0.7 (18)
2 9.3 -  0.8 (12) 14.6 -  1.4 (6) 11.1 - 1.6 (18)
3 9.2 - 0.8 (17) 10.4 - 1.2 (11) 9.3 - 1.0 (12)
Each value represents mean - SEM. Number o f observations are given in 
parentheses.
Mice receiving two in jections were f irs t  in jected 60 minutes before testing, 
and those receiving three in jections had the ir f irs t two in jections 60 and 59 
minutes before testing.
Table 2.3. E ffect of DFP on Hot-Plate Reaction Times in the Mouse
Saline
DFP (lm g/kg) 
DFP (2mg/kg)
H ot-P la te  Latency (Secs) 
Time a fte r In jection
0.3 hours
11.9 - 1.6
9.7 - 0.8
28.4 - 5.6*
1 hour
13.2 - 1.1
9.4 -  0.7
19.0 - 2.0*
2 hours
12.7 -  1.5
11.8 -  1.2
18.7 - 2.8
4 hours
11.7 - 1.0
12.0 - 0.9
33.0 -  8.7*
Each value represents mean - SEM o f at least 6 observations. Unpaired t -  
test vs. saline *p<0.05.
Table 2.4. E ffect of Different Vehicles on the Antinociceptive Activity of DFP
Vehicle used
Peanut O il 
Saline
H ot-P la te  Latency (Secs)
lm g/kg
9.8 - 1.1 9.2 t  2.3
9.4 - 0.7
2mg/kg
18.6 +4.5 
19.0 - 2.0
Each value represents the mean - SEM of 6 observations.
Table 2.5.
Treatm ent
Naloxone
Atropine
Effect of Atropine and Naloxone on 2mg/kg
DFP Induced Antinociception in Mice
H ot-P la te  Latency (secs)
Saline 33.9 - 5.9 (13)
0.1 mg/kg 26.0' -  4.9 (12)
1.0 mg/kg 29.9 - 7.5 (6)
10 mg/kg 33.6 - 5.0 (12)
Saline 28.1 - 2.6 (6)
1 mg/kg 16.4 - 2.1 (6)*
10 mg/kg 16.2 - 3.8 (6)*
20 mg/kg 12.1 - 0.9 (6 )**
Each value represents mean - SEM. Number of observations are in 
parentheses. Unpaired t-te s t vs saline *p<0.005 **p<0.001.
Doses o f naloxone between 0.1 and lOmg/kg had no e ffe c t on the hot-p la te  
reaction times of mice receiving DFP (2mg/kg). However, when mice 
received atropine (1 to 20mg/kg) hot-p la te reaction tim e was s ign ifican tly  
reduced. A 20mg/kg, response times were not s ign ifican tly  d iffe re n t from  
mice receiving saline in jections.
2.13. E ffect of DFP and Drugs Reversing the Effects of DFP on Opioid 
Antinociception in Mice
The antinociceptive ac tiv ities  of morphine, fentanyl and a lfen tan il are shown 
in Table 2.6. A c tiv itie s  are represented in terms o f computed ADj-g values as 
a measure o f antinociceptive potency.
In mice pre-treated w ith  lm g/kg DFP the AD^g values of morphine and 
fentanyl were unaltered. However, a tw o-fo ld  increase in the antinociceptive 
a c tiv ity  o f a lfen tan il (as shown by a reduced AD^g), was observed fo llow ing 
DFP pre-treatm ent.
The atropine-pralidoxim e mix was administered as a trea tm ent fo r DFP 
poisoning. The e ffe c t o f DFP on the antinociceptive ac tiv ities  o f fentanyl 
and a lfen tan il was unaltered by the atropine-pralidoxim e mix trea tm ent, 
however, an increased antinociceptive a c tiv ity  o f morphine (denoted by 
s ign ifican t decreases in AD^g) was observed by this treatm ent.
Diazepam was used as an additional component in the trea tm ent o f DFP 
poisoning. No s ign ificant changes in AD^g values fo r the opioids were 
observed fo llow ing additional adm inistration o f diazepam (Table 2.6.).
Table 2.6. E ffect of DFP (Img/kg) and of Drugs Reversing DFP
Poisoning on Opioid-Induced Antinociception in Mice
A D cn Values
A lfe n ta n il 
(gg/kg) .
329.7 - 23.3
164.3 - 11.0**
175.0 - 1 5 .0 **
207.3 ± 3 3 .0 **
AD^g values are the mean - SEM (of at least 9 observations). AD^g values 
are doses required to increase hot-p la te reaction tim e to 30 seconds and are 
calculated from  the fu ll dose response curves fo r each agonist. Normal 
deviate fo r comparison of means vs. saline **p<0.01; ***p<0.001.
Treatm ent Morphine Fentanyl
(mg/kg) (gg/kg)
Saline 20.7 - 1.9 66.4 - 6.7
DFP 24.7 - 2.5 52.5 - 5.6
DFP + A tropine + 
Pralidoxime
12.0-1.0* 54.3 - 5.9
DFP + Atropine + 
Pralidoxime + Diazepam
10.7 ± 1.7* 53.3 ± 8.3
2.14. E ffect of Atropine and Pralidoxine and Diazepam on Nociception
As a control, atropine-pralidoxim e mix, and diazepam were administered 
alone, to determ ine the ir e ffe c t on mouse hot-p la te latency.
When the atropine-pralidoxim e mix was administered at 1 m inute, w ith  saline 
given at 0 and 30 minutes, testing at 60 minutes gave a response tim e o f 10.5 
- 0.7 seconds (n=12), which is not s ign ifican tly  d iffe ren t from  saline contro l 
values.
The e ffe c t o f diazepam on nociceptive responses is shown in Table 2.7. 
Diazepam did not a ffe c t hot-p la te response times, even at doses which 
produced clear motor incapacitation.
Using a PEG/saline in jection vehicle o£ in jecting saline i.m . did not give hot­
plate reaction times s ign ifican tly  d iffe re n t from  saline s.c. (Table 2.7.)
2.15 E ffect of Neostigmine and Pyridostigmine on Opioid Antinociception
The e ffe c t o f the quaternary anticholinesterase agents neostigmine and 
pyridostigm ine opioid antinociception is shown in Tables 2.8 and 2.9.
Neostigmine did not produce any s ign ifican t potentia tion o f a lfen tan il over 
the dose range studied. Pyridostigm ine pre-treatm ent did not s ign ifican tly  
a lte r AD^g values fo r the opioids studies, though there was a small 
enhancement o f a lfen tan il antinociception (p=0.105).
Table 2.7. E ffect of Intramuscularly-Administered Diazepam
and Injection Vehicle on Hot-Plate Reaction Times in Mice
Treatm ent
Saline
PEG/Saline
Diazepam 6.25 pm ol/kg 
Diazepam 12.5 pmol/kg
H ot-P la te  Response 
Time (Seconds)
8.7 - 1.3 (12)
8.2 - 0.5 (6)
8.7 - 1.6 (6)
10.2 -  2.1 (6)
Values show means - SEM o f hot-p la te response times. Number 
observations is shown in parentheses. PEG = polyethylene glycol.
Table 2.8. E ffect of Various Doses of Neostigmine on the 
Antinociceptive Activity of Alfentanil
Saline
Neostigmine 50gg/kg 
Saline
Neostigmine lOOgg/kg 
Saline
Neostigmine 200gg/kg
A lfe n ta n il AD,-g (gg/kg)
143 - 18 
146 1 13
178 - 13 
170 - 11
155 - 14 
128 - 14
Values are mean + SEM o f 6 observations on hot-p la te reactions times. 
Contro l (saline) AD^g values were obtained on the same day fo r each dose o f 
neostigmine.
Table 2.9. E ffect of Pyridostimine (Img/kg) On Antinociceptive 
Potencies of Morphine,Fentany 1 and Alfentanil
Treatm ent
Saline
Pyridostigm ine
Morphine
(mg/kg)
16.8 - 1.3 
lm g/kg 16.1 - 1.4
AD^g Values 
Fentanyl
(pg/kg)
37.6 - 4.3
36.7 - 2.8
A lfe n ta n il
(pg/kg)
220 -  17.9 
172 - 18.9
Values are mean - SEM of 6 observations on hot-p la te reaction tim es. 
Control (saline) AD ^q values were obtained on the same day fo r each opioid.
Table 2.10.
Treatm ent
A lfe n ta n il
DFP + 
A lfen tan il
Naloxone Antagonism of Antinociception Induced by
Alfentanil With and Without DFP
Naloxone a d 50+s e m Dose Ratio Slope of Apparent pA2 values
(pg/kg) pg/kg pA2 plot (95% confidence in terva
0 0.22 - 0.02
10 0.26 - 0.03 1.18
100 0.57 - 0.07 2.59
1000 3.20 - 0.30 14.55 -1.00 8.30 (8.26 - 8.35)
0 0.13 - 0.07 -
10 0.25 - 0.06 1.92
100 0.56 - 0.06 4.31
1000 3.30 - 0.09 25.39 -0.99 8.95 (6.30 - 11.60)
AD^g values are the mean doses - SEM required to increase hot-p la te reaction tim e to 30 seconds.
2.16 Antagonism of Alfentanil, Alone and With DFP, on Naloxone
The e ffe c t o f naloxone antagonism on the antinociceptive a c tiv ity  o f 
a lfen tan il and the e ffe c t o f naloxone on DFP plus a lfen tan il antinociception 
is shown in Table 2.10.
Naloxone antagonism was measured as 'apparent pA£' according to Hayashi 
and Takemori (1971). The pA2 value represent the a ff in ity  fo r the antagonist 
naloxone fo r its  receptor. The values obtained fo r 'apparent PA21 were very 
s im ilar indicating tha t the compounds were acting through the same 
receptors. The slope o f the pA2 p lo t were very s im ila r to the theore tica l 
value of -1 fo r com petitive  antagonism.
2.17. E ffect of DFP upon Nociceptive Responses in the Rat
Figure 2.3. shows the tim e course fo r the e ffe c t o f DFP adm in istration on the
nociceptive responses o f the ra t in the paw pressure test.
Saline base-line responses remained constant over the tim e studied and w ith  
repeated testing. A t lm g/kg, DFP did not a ffe c t the nociceptive response. 
However, there were s ign ificant (p<0.001) increases in response thresholds fo r 
a ll the tim e points studied fo llow ing DFP at 2mg/kg (Fig 2.3.) A t the 
2mg/kg dose DFP produced clear signs o f anticholinesterase poisoning, such 
as marked tremors. However, the leg w ithdrawal and struggling responses 
were not impaired.
2.18 E ffe c t o f DFP P re-Treatm ent on Opioid Antinociception in Rats
The e ffe c t o f the sub-antinociceptive dose o f DFP (Img/kg) on the 
antinociceptive ac tiv ities  o f morphine, fentanyl and a lfen tan il are shown in 
(Figs. 2.4., 2.5. and 2.6.). DFP pre-treatm ent did not a ffe c t the 
antinociceptive a c tiv ity  o f morphine, but both fentanyl and a lfen tan il were 
s ign ifican tly  potentiated at low doses o f these opioids, (p < 0.01, unpaired t -  
test).
RESSURE(g)
00
0 0 -
00 -
0 0 -
0 0 -
00 -
yy 90 TIME(mins)Pre ao 45 60
Fig. 2.3. Time Course for the Effect of DFP on the 
Nociceptive Responses in the Rat Paw 
Pressure Tests
Closed circles: saline treated animals. Open triangles: 
DFP (lmg/kg) treated animals. Closed triangles: DFP
(2mg/kg) treated animals. Points represent means and 
SEM of 10 observations.
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Fig. 2.4. Effect of DFP on Morphine Antinociception 
in the Rat Paw Pressure Test
The abscissa shows dose for morphine (s.c.) in mg/kg 
Closed circles: control treated. Open circles: DFP 
(lmg/kg) treated. Each histogram represents mean 
and SEM of 10 observations.
Means represent response at peak.antinociceptive times
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Fig. 2.5. Effect of DFP on Fentanyl Antinociception 
in the Rat Paw Pressure Test
The abscissa shows dose for fentanyl (s.c.) in yg/kg.
Closed circles: control treated. Open circles: DFP 
(lmg/kg) treated. Each histogram represents mean 
and SEM of 10 observations.
I Means represent response at peak antinociceptive times
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Fig 2.6. Effect of DFP on Alfentanil Antinocoception 
in the Rat Paw Pressure Test
The abscissa shows dose for alfentanil (s.c.) in yg/kg. 
Closed circles: control treated. Open circles: DFP 
(lmg/kg) treated. Each histogram represents mean 
and SEM of 10 observations.
Means represent response at peak antinociceptive times
DISCUSSION
2.19. Drug Injection Times
The choice o f in jection times and in it ia l doses o f drugs were determined from  
p ilo t experiments or were based on available lite ra tu re .
Neostigmine adm in istration (30 minutes before antinociceptive testing) and 
in it ia l dose were based on studies o f Lawrence and Livingstone (1979).
Pyridostigm ine has a longer duration of action than neostigmine (B ritish  National 
Form ulary, 1983) and so fo r these studies pyridostigm ine was in jected one hour 
before testing. A high dose of lm g/kg O-D^g = 1.3mg/kg mice; Mestinon data 
sheet) was used so tha t any e ffe c t would more like ly  be revealed.
Naloxone was administered 30 minutes before testing, a tim e generally given in 
the lite ra tu re  (eg, Koehn and Karczm ar, 1978).
2.20. E ffect of DFP on Nociceptive Responses in Mice and Rats
Though at lm g/kg DFP did not appear to show any appreciable antinociceptive 
a c tiv ity  in the mouse hot-p la te test, at 2mg/kg the increase in hot-p la te  reaction 
tim e was marked. This apparent antinociceptive a c tiv ity  o f DFP was long- 
lasting. However, at this higher dose mice showed pronounced signs o f 
anticholinesterase poisoning, including tremors and fasiculations, decreased 
ambulation and apparent sedative ataxia. The nociceptive response in the hot­
plate test involves the animal lif t in g  and lick ing one or more of its  paws. As this 
response requires a complex set of co-ordinated non-reflexive movements, i t  is 
possible tha t the apparent antinociceptive e ffe c t observed fo r DFP a t 2mg/kg
was due to impaired muscular function. This im pairm ent could be o f centra l 
origin, eg, disruption of contro l of movement or peripheral orig in, eg, muscular 
weakness, or indeed, both.
I t  has been reported that in rats at 2mg/kg s.c. DFP caused hind-lim b abduction 
(Fernando et al, 1984) and at 2.2mg/kg i.m . the animals appear behaviourally 
depressed and le tharg ic (Samson, 1984). Even at doses below lm g/kg, DFP is 
reported to produce physical incapacita tion (Harris and S titcher, 1984). I t  is not 
unreasonable to presume from  observations in this study and the available 
lite ra tu re , tha t DFP adm in istration could im pair the nociceptive response 
w ithout necessarily possessing antinociceptive a c tiv ity . The e ffe c t o f DFP on 
the locomotor a c tiv ity  of mice and the im plications in nociceptive testing is 
given fu ll consideration in Section 3.13.
The data presented in this thesis are consistent w ith  the findings o f Cox and Tha 
(1972) who did not observe any antinociceptive fo r DFP up to 2mg/kg in the 
mouse hot-p late test.
In contrast, studies in the ra t indicate tha t DFP is antinociceptive in this 
species. Doses as low as 0.lm g/kg s.c. have been shown to induce antinociception 
in the ra t hot-p la te test (Koehn et al, 1980) and 0.5mg/kg s.c. in the ra t ta il f lic k  
test (Koehn and Karczm ar, 1978). The results presented in this thesis show tha t 
DFP at 2mg/kg produced marked antinociception in the paw pressure test. 
Though this antinociceptive dose is much higher than tha t reported by Koehn et 
al (1980), this may be a re flec tion  on the use o f pressure as the nociceptive 
stimulus. The nociceptive response to pressure is believed to be predom inantly 
mediated through k -opioid receptors, whilst heat noxia are believed to act 
through p-opioid receptors (Tyers, 1980; Upton et al, 1983).
The observation tha t naloxone up to lOmg/kg did not a lter the reaction tim e 
fo llow ing adm in istration o f DFP (Table 2.3.) suggests tha t the apparent 
antinociceptive a c tiv ity  o f DFP. is not mediated through an opioid system. 
A tropine, however, did antagonize the increased latencies, and at 20mg/kg 
to ta lly  reversed DFP's e ffe c t. The apparent antinociceptive a c tiv ity  is therefore 
only mediated via muscarinic receptors and this contrasts w ith  e ffec ts  in the ra t 
where both opioid and muscarinic receptors mediates its  action (Koehn and 
Karczm ar, 1978).
Clear species differences emerge, w ith  mice being insensitive to an 
antinociceptive action o f DFP w h ils t in rats, DFP may product potent 
antinociception.
2.21. E ffect of DFP on Morphine Antinociception
DFP had no e ffe c t on morphine antinociception (Table 2.6.) and this contrasts 
w ith  the findings o f Bhargava and Way (1972). They reported po tentia ting  
a c tiv ity  o f DFP upon morphine antinociception, though i t  should be stressed tha t 
these effects, while consistent, fa iled to reach s ta tis tica l significance. The 
possibility o f vehicle-re la ted e ffects  must be entertained since Bhargava and 
Way (1972) used peanut o il fo r DFP adm in istration and 0.9% saline was used in 
the experiments described in this thesis. However, though peanut o il has been 
shown to induce sedation (Pinsky et al, 1982) no antinociceptive e ffec ts  fo r DFP 
in th is vehicle could be shown (Table 2.4.) and this possibility can be re a lis tica lly  
excluded.
A t a dose of 0.2mg/kg, Saxena (1938) found that DFP did not potentia te  morphine 
in the ra t ta il c lip  test. Though there are many reports o f cholinerg ic drugs 
potentia ting opioid antinociception (see Table 1.2.) the available data appears to 
m ilita te  against a potentia ting e ffe c t o f DFP in morphine-induced 
antinociception.
2.22. Effect of DFP on Fentanyl and Alfentanil Antinociception
Though the a c tiv ity  of the synthetic opioid analgesic fentanyl was not found to 
be potentia ting by DFP in the mouse hot-p late test, the s truc tu ra lly -re la ted  
compound a lfen tan il was potentia ted tw o-fo ld  (Table 2.6.).
In addition, a lfen tan il antinociception in the ra t paw pressure test appeared to be 
potentiated by DFP pre-trea tm ent. Though this potentia ting e ffe c t was only 
observed at low doses o f a lfen tan il, i t  seems like ly  tha t employment o f a c u t-o ff  
weight masks potentia tion at higher doses. This problem was also encountered in 
the hot-p la te data (see Section 2.11.1).
Fentanyl also appeared to be potentiated in rats by DFP in the same way as 
a lfen tan il. So a lfen tan il is potentiated by DFP in both mouse and ra t 
antinociceptive test, though fentanyl was only potentiated in the ra t. This could 
be a re flec tion  o f d iffe ren t nociceptive mechanisms in the ra t compared to those 
in mice.
2.23. Proposed Mechanisms fo r DFP Potentia tion o f A lfe n ta n il
Though morphine, fentanyl and a lfen tan il are a ll p rim arily  u-opioid agonists, 
DFP has been shown in this study to have a d iffe re n tia l potentia ting e ffe c t on 
these opioids. There are several ways by which DFP could potentia te the 
a c tiv ity  o f opioids; these are a lterations in absorption, d is tribu tion, receptor 
action, metabolism or excretion.
2.23.1. Absorption
There are a number o f factors which a ffe c t absorption of drugs from  s.c. 
in jection sites. A major fac to r is cutaneous blood flow  and DFP trea tm ent is 
believed to decrease c ircu la to ry  rate (Ramachandran, 1967). In addition, DFP 
dose dependently induces hypothermia (Kenley, e t al, 1982) which would decrease 
peripheral blood flow . These factors would tend to reduce drug absorption from  
a s.c. site and furtherm ore would not d iscrim inate between the opioids studied. 
I t  is also probable that drug absorption is not a lim itin g  fac to r fo r fen tanyl and 
a lfen tan il. Both these drugs are lipid-soluble w ith  octanokw ater p a rtition  
coeffic ien ts  o f 860 and 130 fo r fentanyl and a lfen tan il respective ly (Meuldemans 
et al, 1982). Morphine has low lip id  so lub ility  w ith  an octanokw ater p a rtition  
coe ffic ien t o f 1.42 (Kaufman et al, 1975). A d iffe re n tia l in te raction  between 
DFP and a lfen tan il at the site o f in jection is therefore unlike ly.
2.23.2 D is tribution
Many drugs are bound to plasma proteins and may compete fo r the same binding 
sites. Such com petition could result in displacement and altered 
pharmacokinetic behaviour o f one drug. This type of drug in te raction  would be 
pa rticu la rly  im portant fo r drugs which have high frac tiona l binding (see 
MacKichan, 1984 fo r  review).
Both fentanyl and a lfen tan il have high frac tiona l binding to blood proteins 
(Meuldemans, 1982) as does DFP (M artin, 1985). I t  is possible tha t DFP could 
displace a lfen tan il from  binding sites, allowing more a lfen tan il to enter the 
brain. This possib ility was studied and is described in Chapter 5.
2.23.3 Receptor Action
DFP may act at the receptor level to increase the potency o f a lfen tan il. For 
example, DFP may be producing opioid receptor super-sensitivity to a lfen tan il. 
P ilo t binding studies using a lfen tan il were performed, but were inconsistent. 
This is most probably due to the very rapid dissociation from  the receptor site 
tha t has been reported fo r this ligand (Leysen et al, 1983).
In fac t, an in te raction  between DFP at the receptor level would not explain the 
d iffe re n tia l action o f DFP on a lfen tan il, since a ll three opioids studied exert 
pharmacological e ffec ts  through p-opioid receptors (Upton et al, 1983; Leysen et 
al, 1983).
2.23.4. Metabolism
In addition to being a potent inh ib ito r o f cholinesterase, DFP may w e ll in h ib it 
other enzymes including those involved in drug metabolism (see O’N e ill, 1981). 
For example, a s ign ificant inh ib ition o f m itochondrial aldehyde dehydrogenase 
occurs fo r at least 85 days fo llow ing adm inistration o f 0.5mg/kg DFP (Messiha, 
et al, 1983).
DFP potently inhib its the enzymes hydrolysing substance P (Kato et al, 1980) and 
metabolising enkephalins (Snead et al, 1980). A lfen tan il is rapid ly metabolised 
fo llow ing i.v. adm inistration, w ith  50-60% metabolised a fte r 4 minutes (M ichie ls 
et al, 1981) by N -dealkylation and O-demethylation (Meuldemans, 1980). However
the term ination of a lfentan il's  action is predominantly dependent on a 
red istribu tion mechanism (Stanski and Hug, 1982). I t  is conceivable tha t DFP 
could inh ib it the enzymes responsible fo r the metabolism of a lfen tan il, thereby 
increasing its  antinociceptive a c tiv ity . However, i t  must be borne in mind tha t 
antinociceptive testing was carried out five  minutes a fte r a lfen tan il 
adm inistration and over such a short tim e period, DFP would have to be a very 
potent inh ib ito r to produce a tw o-fo ld  potentia tion o f a lfen tan il.
2.23.5.Excretion
If, as mentioned above, red istribu tion  is the main means o f te rm ination  o f 
action, an in te raction  between DFP and a lfen tan il in excretion processes would 
probably not a ffe c t a lfen tan il action. Moreover in rats only 0.2% o f the parent 
drug is excreted in the urine (Meuldemans, 1980b), and so i t  is un like ly tha t 
impaired renal excretion would have any e ffe c t on the antinociceptive a c t iv ity  
o f a lfen tan il.
2.24. Effect of Atropine and Pralidoxime on DFP Potentiation of Alfentanil 
Antinociception
The potentia ting e ffe c t o f DFP on a lfen tan il antinociception may be independent 
o f an action on the cholinergic system as the adm inistration o f the m uscarinic 
receptor antagonist atropine and pralidoxime to regenerate cholinesterase 
enzymes did not a lte r the AD ^q value fo r DFP plus a lfen tan il. However, 
pralidoxime is unable to cross the blood-brain barrier, so tha t brain 
cholinesterase would remain largely inhib ited by DFP even a fte r pralidoxim e 
adm inistration. Though atropine would block muscarinic receptors, i t  is possible 
tha t an in teraction between DFP and a lfen tan il could involve unprotected 
centra l n ico tin ic  receptors. Other possibilities regarding the nature o f DFP and 
a lfen tan il in teraction are given in Section 4.11.
2.25. E ffe c t o f A trop ine and Pralidoxim e on the A n tinociceptive  A c t iv ity  o f 
Morphine
DFP alone did not a ffe c t the AD^g fo r morphine, but when atropine and 
pralidoxime was also administered morphine's antinociceptive a c tiv ity  was 
enhanced. As mentioned in Section 2.24., the atropine-pralidoxim e mix does not 
pro tect centra l n ico tin ic  receptors and so i t  may be tha t by blocking the 
muscarinic receptors w ith  atropine, more o f the non-metabolised acetylcholine 
would be able to in te rac t w ith  n ico tin ic  receptors. In other words, the presence 
o f a muscarinic antagonist in a cholinesterase inhib ited system could lead to 
increased n ico tin ic  response. In consideration o f this, i t  is worth noting tha t 
there have been several studies in mice, ra t and dog showing potent 
antinociceptive a c tiv ity  o f n ico tin ic  agonists (see Table 1.3.).
This in teraction, however, would have to be specific fo r morphine and the 
n ico tin ic  response since neither fentanyl or a lfen tan il had altered AD^g 
fo llow ing atropine and pralidoxime.
An a lte rna tive  explanation fo r these findings is tha t morphine may be in te rac ting  
w ith  atropine. Indeed, i t  has been reported tha t in the ra t hot-p la te  test, 
atropine at 2mg/kg s ign ifican tly  potentiated the antinociceptive a c tiv ity  o f 
morphine (Malec and Langwinski, 1982). This report also notes tha t atropine did 
not a lte r the antinociceptive a c tiv ity  o f fentanyl or o f pentazocine. The results 
of this study showing d iffe re n tia l potentia tion o f morphine antinociception by 
atropine are supportive o f the results presented in this thesis.
An additional mechanism for the potentia tion of morphine by atropine which 
should be considered is that respiratory alkalosis enhances the percentage of 
unionised morphine in the c ircu la tion  and thereby increasing the amount entering
the brain (Schulman et al., 1984). I t  is possible tha t the additional adm in istra tion 
of atropine and pralidoxime produces a degree o f respiratory alkalosis, which 
through pharmacokinetic mechanisms potentiates the antinociceptive a c tiv ity  o f 
morphine plus DFP.
2.26. Effect of Diazepam on the Antinociceptive Activity of Opioids in Mice 
Receiving DFP, Atropine and Pralidoxime
Diazepam administered alone did not produce any increase in ho t-p la te  la tency 
in the mouse. Diazepam has, in fac t, been reported to possess antinociceptive 
a c tiv ity  in humans (Haas et al, 1979) though at doses much higher than those 
described in this thesis.
Diazepam has been shown to both reduce (Mantegazza, 1982) and to potentia te  
(M atla and Langwinski, 1982) the antinociceptive a c tiv ity  o f opioids including 
morphine and fentanyl. In this study, co-adm in istration of diazepam did not 
a lte r the AD^g values o f the three opioids studied. I t  should be realised, 
however, tha t the animals were receiving four d iffe ren t drugs in addition to the 
opioid, so tha t any e ffects  o f diazepam on antinociceptive ac tiv itie s  could be 
obscured by non-specific drug in teractions.
2.27. Variation in Antinociceptive Potency of Alfentanil in Mice
The values given fo r AD^g scores fo r a lfen tan il in Tables 2.6. and 2.8. are 
d iffe ren t. The orig in of this disparity is not obvious as the animal stra in, test 
conditions and experimentor were the same fo r both sets of experiments. Two 
differences do exist however, and these are, f irs tly , tha t d iffe re n t a lfen tan il 
batches were used and, secondly, these experiments were carried out at d iffe re n t
tim es of the year. Considering the second proposition, i t  has been reported tha t
stim ulation-induced antinociception is subject to circadian varia tion  (Buckett,
1981) and this has been confirm ed w ith  morphine using the same species and
apparatus described in this thesis (P.G.Green, unpublished observations). In
addition, there are reports of circannual varia tion in opioid response as Buckett
(1981) reports tha t stim ulation-induced antinociception as measured by latencies
in mice vary throughout the year. In v itro  response of vasa deferentia  to
2 5morphine and D -A la  , Met enkephalinamide have also been shown to exh ib it 
circannual varia tion, w ith  a five -fo ld  varia tion in potency (De Ceballos and De 
Felipe, 1984). The varia tion o f a lfen tan il potency is also considered in Section
5.18. This in form ation described above highlights the importance o f carrying out 
appropriate controls in para lle l w ith  the experiment.
CHAPTER 3
Locomotor Activity of Mice 
Effect of DFP and Drugs Used in the Treatment of DFP Poisoning
INTRODUCTION
3.1 Assessment of Drug Effect on Spontaneous Locomotor Activity
As a behavioural measure, locom otor a c tiv ity  is probably one o f the most 
simple. Its s im p lic ity  enables many experiments to be carried out 
simultaneously and data to be collected autom atica lly. On the other hand, its  
s im p lic ity  means tha t only general ambulation is measured and in form ation 
on stereotypic resonses (eg, sn iffing  and grooming), co-ordination and 
muscular r ig id ity  cannot be recorded. I t  is well known tha t po ten tia lly  useful 
in form ation goes unrecorded (Krsiak et al, 1970). The in form ation gained 
from  these locomotor studies should therefore be viewed as only a basic 
measure o f a lterations in behaviour and too detailed an in te rp re ta tion  o f the 
results should be avoided. Nevertheless, w h ils t bearing in mind the 
lim ita tions  o f these techniques, drug-inducing a ltera tion o f locom otor 
function does give an indication of certa in  drug-receptor in teractions w ith in  
the centra l nervous system. Indeed, i t  has been suggested tha t in order to 
assess the behavioural e ffects  o f a drug, data must be obtained on its  
influence on spontaneous m otor a c tiv ity  (Robbins, 1977).
Data presented in this thesis shows tha t DFP at 2mg/kg produced apparent 
antinociception (Table 2.3.). Though the hot-p la te reaction tim e was 
s ign ifican tly  increased compared to saline controls, mice exhibited reduced 
ambulation and muscular weakness (as evidenced by hind limb abduction). I t  is 
possible tha t impaired muscular function and co-ordination could delay the 
nociceptive end-point (the licking response). Experiments were therefore  
devised to assess the e ffects  of DFP on spontaneous motor a c tiv ity , and 
a c tiv ity  fo llow ing opioid adm inistration. The e ffects  o f drugs used in 
trea ting anticholinesterase poisoning were also assessed fo r e ffec ts  on 
locomotor a c tiv ity .
MATERIALS AND METHODS
3.2. Animals and Experimental Conditions
Male albino mice (CD-I strain; 25-30g) were used as described in Section
2.2.1. Procedures fo r equ ilibration were also as those previously described.
3.3. Drugs
The drugs used were obtained from  sources listed in Section 2.6.
3.4. Dosing Protocols
Mice were in jected subcutaneously using the same tim ings to para lle l the 
antinociceptive procedures described in Section 2.3.3. Doses o f opioids used 
were 20mg/kg morphine, 80ug/kg fentanyl and 400pg/kg a lfen tan il.
3.3. Locomotor Activity Testing
Locomotor a c tiv ity  in mice was measured using a system identica l to tha t 
described by Francis et al (1983) in which a photobeam m onitoring system was 
linked to a m icrocomputer. The apparatus consisted of pairs o f industria l 
grade in fra -red  source and detector pairs. Three in fra -red  ligh t beams cross 
each test box 0.3cm above the box base, and are detected by appropriate 
sensors. When the beam path is blocked or unblocked, a score is registered. 
Data is collected and displayed on a m icrocom puter (BBC B) via an in te rface . 
The software employs an in te rrup t routine to assess the state o f the 
photocells (on or o ff) every 10ms, and a change in state is recorded as a score.
Locomotor hardware was b u ilt in the B iochem istry Workshops, U nivers ity  of 
Surrey. O riginal software w ritte n  fo r this apparatus was adapted to display 
the mean and standard deviation of counts (see Appendix C fo r listing).
Individual mice were placed in each testing box (18.3 x 11cm), allowing five  
mice to be tested simultaneously. Locom otor a c tiv ity  was measured 
im m ediate ly a fte r the last in jection, w ith  the exception o f some experiments 
where DFP or saline were in jected 1 hour before testing. In jection tim ings 
were the same as those described in Section 2.2.3.(a). Testing was m onitored 
fo r 15 5-m inute epochs, so tha t changes in a c tiv ity  over tim e could be 
assessed.
3.6. Statistical Procedures
Locomotor scores were analysed fo llow ing data reduction. Mean locom otor 
scores fo r each 5-m inute period were summed over the f irs t 15 and to ta l 75 
minute periods. Means fo r the 15 and 75 m inute periods were obtained from  
10 or 15 animals recorded on one, two or three separate days.
E ffe c t o f drug trea tm ent was analysed using m ultip le  analysis of variance 
followed by a posteriori examination using Duncan's M ultip le  Range Test 
(Duncan, 1955). These s ta tis tica l analyses were carried out using the SPSS 
software on the University 's Prime computer (S ta tis tica l Packages fo r the 
Social Sciences, Pennsylvania State University, Version M, Release 9.1.).
RESULTS
3.7. E ffect of DFP on Locomotor Activity
DFP at lm g/kg produced a s ign ificant decrease in locomotor a c tiv ity  only 
over 75 minutes compared to saline (Figure 3.1. and Figure 3.2.). However, 
when DFP was in jected 1 hour before testing, DFP s ign ifican tly  decreased 
exploratory a c tiv ity  over the f irs t  15 minutes. This depression o f locom otor 
a c tiv ity  was fu rthe r decreased fo llow ing DFP 2mg/kg .
3.8. E ffect of Atropine and Pralidoxime on Locomotor Activity
The atropine-pralidoxim e m ix produced hyperlocomotion which was not 
decreased in animals pre-treated w ith  DFP. The e ffe c t o f DFP alone was 
reversed by the atropine-pralidoxim e m ix adm inistration.
3.9. E ffect of Diazepam on Locomotor Activity
Diazepam alone greatly depressed locomotor a c tiv ity  and fu rthe r decreased 
the hyperlocomotory e ffe c t o f DFP.
3.10. Effect of Various Treatments on Alfentanil Induced Hyperlocomotion
The hyperlocomotion fo llow ing a lfen tan il adm inistration was s ign ifican tly  
decreased by DFP (Fig. 3.3.).
Over the f irs t  15 minutes, atropine-pralidoxim e mix adm in istra tion did not 
s ign ifican tly  a lte r the DFP e ffe c t, but over 75 minutes there was a reversal, 
w ith  increased locomotor a c tiv ity . The additional in jection o f diazepam 
produced a marked decrease in a c tiv ity .
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Fig 3.1. Graph Showing the Effect of Various Drug 
Treatments on Locomotor Activity in Mice
Close circles: saline controls. Closed triangles: 
DFP (lmg/kg) treated. Open triangles: DFP (2mg/kg) 
treated. Open squares: morphine (20mg/kg) treated. 
Each graph represents the mean of at least 10 
observations.
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Fig 3.3. Effect of DFP on Alfentanil-induced
hyperlocomotion over 15 and 75 minutes
Black histograms: 
Grey histograms: 
SAL + ALFENT:
DFP + ALFENT:
DFP + ATR/PR 
+ ALFENTANIL:
locomotor score over 15 minutes 
locomotor score over 75 minutes 
Saline and alfentanil treated. 
DFP and alfentanil treated.
DFP, atropine and pralidoxime 
and alfentanil treated.
DFP + DIAZ
+ A/P + ALF: DFP, diazepam, atropine and
pralidoxime and alfentanil 
treated.
Values represent mean - S.E.M. o f at least 10 observations.
Saline contro l scores: 15 mins 1442 -  108
(n=5) 75 mins 5630 ^479
3.11. E ffect of Various Treatments on Fentanyl Induced Hyperlocomotion
The hyperlocomotory a c tiv ity  o f fentanyl was not s ign ifican tly  altered by 
adm in istration o f DFP or DFP + atropine/pra lidoxim e over 15 or 75 m inute 
periods (Fig. 3.4.). The additional in jection o f diazepam, however, 
s ign ifican tly  depressed locom otor a c tiv ity  scores.
3.12. E ffect of Various Treatments on Morphine Induced Hyperlocomotion
Morphine-induced hyperlocomotion was s ign ifican tly  decreased fo llow ing DFP 
pretreatm ent, but only over the 75 m inute period (Fig.3.5.). The atropine- 
pralidoxime m ix had no e ffe c t on morphine hypolocomotion. Diazepam 
produced marked decreases in locom otor scores, and though this was 
s ign ificant over the f irs t 15 minutes s ta tis tica l s ign ificant differences were 
not observed over the 75 minutes, despite there being nearly a 34-fo ld 
d ifference; very high pooled standard deviations existed in these groups.
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Fig. 3.4. Effect of DFP on fentany1-induced
hyperlocomotion over 15 and 75 minutes
Black histograms 
Grey histograms: 
SAL + FENT:
DFP + FENT:
DFP + ATR/PR 
+ FENTANYL:
DFP + DIAZ 
+ A/P + FENT:
locomotor score over 15 minutes 
locomotor score over 75 minutes 
Saline and fentanyl treated.
DFP and fentanyl treated.
DFP, atropine and pralidoxime 
and fentanyl treated.
DFP, diazepam, atropine and 
pralidoxime and fentanil 
treated.
Values represent mean t  S.E.M. o f at least 10 observations.
Saline contro l scores: 15 mins 1384 -  141
75 mins 5957 -  ~531
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Fig 3.5. Effect of DFP on morphine-induced
hyperlocomotion over 15 and 75 minutes
Black histograms 
Grey histograms: 
SAL + MORPH:
DFP + MORPH:
DFP + ATR/PR 
+ MORPHINE:
locomotor score over 15 minutes 
locomotor score over 75 minutes 
Saline and morphine treated.
DFP and morphine treated.
DFP, atropine and pralidoxime 
and morphine treated.
DFP + DIAZ 
+ A/P + MORPH: DFP, diazepam, atropine and 
pralidoxime and morphine 
treated.
Values represent mean - S.E.M. of a t least 10 observations.
Saline contro l scores: 15 mins 1541 -  122
(n=15) 75 mins 6095 - 404
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DISCUSSION
3.13. E ffect of DFP on Locomotor Activity
There are several reports in the lite ra tu re  describing the e ffec ts  o f 
anticholinesterase agents in im pairing or reducing ambulatory behaviour in 
rodents. This e ffe c t has been shown fo r DFP (Koehn and Karczm ar, 1977, 
1978; Koehn et al, 1980; Raslear and Kaufman, 1983; Samson, 1984; M artin , 
1985), physostigmine (Chaturvedi, 1984; Gonzales, 1984; Harris e t al, 1984; 
Wolthuis and Vanworsch, 1984), pyridostigm ine (Harris et al, 1984; Wolthuis 
and Vanworsch, 1984), sarin (Landauer and Romano, 1984b), soman (Wolthuis 
and Vanworsch, 1984) and tabun (Landauer and Romano, 1984a; Wolthuis and 
Vanworsch, 1984). The w e ll documented e ffe c t o f cholinergic agents on 
locom otor a c tiv ity  has been described as a le rt non-m otile behaviour (ANMB) 
(Karczmar, 1977) and is believed to involve a cholinergic-dopam inergic dipole 
in n ig rostria ta l and extrapyram idal pathways.
In this study, s ign ificant and marked decreases in locomotor a c tiv ity  were 
observed fo r DFP at lm g/kg in mice. When administered 1 hour before testing 
to paralle l the antinociceptive testing procedures, DFP reduced exploratory 
motor a c tiv ity . In in terpre ting the consequences of this data, i t  is not 
unreasonable to suggest tha t DFP induced 'antinociception' was observed as a 
result of impaired motor co-ordination and muscular function ra ther than an 
inh ib ito ry  action on nociceptive systems. This suggestion gains credence 
when the antagonist data is taken into consideration (Table 2.5). The opioid 
antagonist naloxone did not a lte r the DFP antinociception but atropine which 
reversed the hypolocomotor e ffec ts  of DFP (see below), also reversed 
antinociceptive a c tiv ity .
3 . 1 4 . Effect of Atropine and Pralidoxime Alone and With DFP on Locomotor Activity
DFP induced reduction o f locom otor a c tiv ity  appeared to involve the 
cholinergic system as DFP's e ffec ts  were com pletely reversed fo llow ing 
atropine-pralidoxim e mix adm in istration. When administered alone, atropine 
and pralidoxime produced hyperlocomotion. Hyperlocomotion has been 
previously reported fo r atropine (Chatervedi, 1984; Seidel et al, 1979) and fo r 
another muscarinic antagonist, hyoscine (Sansone, 1983; Kuribara and 
Tadokar, 1983).
3.15. Effect of Diazepam Alone and With DFP on Locomotor Activity
Inh ib ition o f locomotor a c tiv ity  fo llow ing diazepam adm inistration was 
marked and this is in contrast w ith  some reports in the lite ra tu re . For 
example, i t  has a c tiv ity  been shown tha t in mice, diazepam up to Im g/kg did 
not a ffe c t locomotion (Sansone, 1982). In rats at 2.5mg/kg diazepam enhanced 
ambulatory a c tiv ity  w hilst at 20mg/kg i t  was inhib ited (Matsubara and 
Matshushita, 1982). In this study the dose of diazepam used was 1.78mg/kg, 
which suggests tha t a marked motor depression was observed, m ice may be 
more sensitive than rats to the locomotor depressant action o f diazepam. 
When administered a fte r DFP the locomotor a c tiv ity  o f diazepam was 
decreased s t ill fu rthe r, so tha t the hypolocomotory e ffects  o f these drugs 
were addictive.
3.16. Effects of DFP on Opioid-Induced Hyperlocomotion
The action o f opioids in mice is to produce a stereotypic running response (eg, 
C arro ll and Sharp, 1972) and in this study morphine, fentanyl and a lfen tan il a ll 
produced this running response. This hyperlocomotion was reduced fo r a ll 
opioids by DFP pretreatm ent. This is consistent w ith  the lite ra tu re  as DFP
at 2mg/kg has been reported to decrease morphine-induced running in mice 
(Su and Loh, 1975). and oxotremorine has also been shown to decrease 
morphine hyperlocomotion (Seidel, 1979). I t  has been suggested tha t the 
augmentation of the opioid-induced running response by cholinergic agents 
may be due to an increase in dopamine u tiliza tio n  produced by muscarinic 
agonists (Seidel, 1979).
The data indicates tha t the e ffe c t o f DFP on opioid induced running is most 
pronounced w ith  a lfen tan il. However, i f  DFP was enhancing the e ffe c t of 
a lfen tan il in the same way as tha t observed fo r the antinociceptive a c tiv ity , 
one m ight have expected increased locomotor scores. A possible explanation 
o f this apparent anomaly highlights a drawback encountered in this form  of 
measurement o f locomotor a c tiv ity . Observation o f mice receiving opioids, 
especially a lfen tan il, revealed tha t during peak opioid a c tiv ity  mice had 
running f its  ie, periods of intense running a c tiv ity  interspersed w ith  periods 
o f im m ob ility  (c f. dopamine catatonia). These periods o f catatonia appeared 
w ith  greater frequency and duration w ith  increasing dose, at 800pg/kg, ha lf 
or sometimes all o f the 60 seconds antinociceptive testing period m ice were 
catatonic. I f  DFP potentiated a lfen tan il, the measured locomotor a c tiv ity  
score could have been reduced fo llow ing DFP i f  the mice spent a greater 
proportion of the ir tim e in a catatonic im m obile state. A c t iv ity  is not a 
unitary measure and photocell measured locomotor a c tiv ity  cannot detect 
such stereotyped ac tiv ities  such as c irc ling , excessive grooming, lick ing  or 
b iting or d iffe ren tia te  between walking and running ac tiv ities . More 
sophisticated a c tiv ity  monitors or scored human observation would be 
required to iden tify  these specific changes in a c tiv ity . So i f  DFP potentia ted 
a lfentanil's a c tiv ity  and produced increased catatonia, this would be re flec ted  
in a decreased locomotor a c tiv ity  score.
3.17. The Effect of Atropine and Pralidoxime on the Locomotor Activity of
DFP and Opioid-Treated M ice
In DFP and opio id-treated mice the e ffe c t o f the atropine-pralidoxim e mix 
trea tm ent on locom otor a c tiv ity  was only s ign ificant fo r a lfen tan il over 75 
minutes. I t  is quite like ly  tha t no s ign ificant e ffe c t was observed fo r the 
other opioids due to the in te raction  o f the four drugs administered and the ir 
e ffects  on locomotor a c tiv ity . For example, the atropine-pralidoxim e m ix in 
addition to possessing hyperlocom otory a c tiv ity  (see Section 3.18.), would 
tend to antagonize the hypolocomotory e ffects  o f DFP. This antagonism of 
DFP could therefore decrease the incidence o f a lfen tan il catatonia (see 
Section 3.20.). Furtherm ore, atropine is reported to potentia te morphine- 
induced c irc ling  (Seidel, 1979).
In summary, the combination o f opioid, DFP, and the atropine-pralidoxim e 
mix produce a complex e ffe c t on locomotor behaviour. The observed 
enhancement of a lfen tan il locomotion w ith  atropine-pralidoxim e m ix is like ly  
to have been a result o f both a reduced degree o f catatonia and an add itive 
cholinergic hyperlocomotion.
3.18. E ffe c t o f Diazepam on Opioid-Induced Locomotion
The large decrease in locomotor score fo llow ing diazepam was common to a ll 
three opioids studied. This e ffe c t has been reported previously fo r morphine- 
and fentanyl-induced hyperlocomotion (M atla and Langwinski, 1982). 
Benzodiazepines are known to have a sedative action and i t  could w e ll be this 
action on benzodiazepine GABA receptors which produced the decrease in 
locom otor score. A lte rna tive ly , diazepam could be acting through another 
receptor system; the role of the dopaminergic system has already been
mentioned in its  involvement in locomotor a c tiv ity  (Section 3.17.) and i t  is 
possible tha t the observed e ffe c t o f diazepam on locomotion was due to its  
action inh ib iting  dopamine function (Reubi et al, 1977). I t  may also be 
possible tha t opioid catalepsy (and hence im m obility ) was enhanced fo llow ing 
diazepam, as catalepsy has been shown to involve inh ib ition of the centra l 
dopaminergic pathway (Kushinsky and Hornykiew icz, 1972).
3.19. Interpretation of Locomotor Data
Locomotor measurement is a s im plis tic  measure o f a ltera tion o f behaviour. 
I t  is subject to many errors and i t  is well known tha t large quantita tive  
differences between individual animal a c tiv ity  scores are observed (Izazole- 
Conde et al, 1983).
Observation of animals during locom otor testing procedures suggested tha t at 
least part of the large varia tion o f scores between animals were probably due 
to behaviours such as grooming. Mice were occassionally observed to be 
grooming d irec tly  in the path o f the in fra -red  lig h t beam so tha t th e ir rapid 
head movements increased the locom otor score.
As mentioned above, production o f catalepsy is produced w ith  high doses o f 
opioids and would tend to increase varia tion between animals. This form  of 
error has been reported in the lite ra tu re  where alcohol at certa in  doses 
produces unchanged or increased locomotor a c tiv ity  and simultaneously large 
increases in im m ob ility  (Smoothy and Berry, 1984). Observation revealed tha t 
this was due to alcohol's e ffe c t of decreasing non-locomotor a c tiv ity  such as 
rearing which is not recorded by simple locomotor a c tiv ity  monitors. These 
lim ita tions  notwithstanding, the locomotor a c tiv ity  m onitor used in this study 
gave a general indication o f the effects o f drugs on locomotor a c tiv ity  o f 
mice.
CHAPTER 4
Distribution of H  Morphine, Fentanyl and Alfentanil 
In Mouse Brain: E ffect of DFP Administration
INTRODUCTION
4.1 Distribution Studies
The d iffe re n tia l potentia tion o f a lfen tan il by DFP led to the conclusion tha t 
the mechanism probably involved an e ffe c t on pharmacokinetics (Section 
2.28) ra ther than altered pharmacodynamic parameters. A simple measure of 
d is tribu tion u tilizes radiolabel tracing methodologies, wherein plasma and 
brain levels o f a radiolabelled drug are determined. Drug concentration in 
contro l and treated animals can then be compared.
A drawback to the method used in this thesis is tha t only to ta l ra d io ac tiv ity  
was determined. The presence o f radioactive m etabolites, which may or may 
not possess pharmacological a c tiv ity  are not distinguished. However, fo r 
fentanyl and a lfen tan il the short tim e period between adm in istration o f the 
drug and k illing  would mean tha t i t  is like ly  tha t the m a jo rity  o f the 
rad ioac tiv ity  in the brain is the parent drug. For morphine the glucuronide 
metabolites do not contribute s ign ifican tly  to uptake in to the brain of 
labelled morphine (H artv ig  et al, 1984). However, morphine-3-glucuronide 
does possess some antinociceptive a c tiv ity  (P.G.Green, unpublished 
observations).
MATERIALS AND METHODS
4.2. Animals and Experimental Conditions
Male albino m ice (CD-I strain; 25-30g) were used as described in Section
2.2.1. Procedures fo r equ ilibration were also as those previously described.
Radiolabelled morphine and fentanyl were supplied in ethanol, and 
radiolabelled a lfen tan il was suplied in w a te r:ace ton itrile  30/70, ethanol 100. 
The solvent was removed under a gentle stream o f dry nitrogen at room 
temperature.
4.3. Drugs
The drugs used were obtained from  sources described in Section 2.4. In 
addition, the fo llow ing radiolabelled compounds were used:-
DRUGS
^ H Morphine sulphate 
Specific A c t iv ity  20-24 C i/m m ol
Amersham International
3 H Fentanyl c itra te
Specific A c t iv ity  15-18 C i/m m ol
IRE, Fleurus (Belgium)
3 H A lfe n ta n il hydrochloride 
Specific A c t iv ity  23.1 C i/m m ol
Janssen Pharmaceuticals
3 H Hexadecane tr it iu m  standard Amersham International
Specific A c t iv ity  1.69 qC i/m l
*  3 H A lfen tan il was generously donated by Janssen Pharmaceutical
4.4. Dosing Protocols
Drug adm in istration procedures were carried out by identica l to tha t 
described in Section 2.6. fo r DFP and opioid adm in istration.
Mice received either 0.9% w /v saline or DFP (Img/kg) s.c. This was followed 
by s.c. in jections o f radiolabelled morphine, fentanyl or a lfen tan il 
administered 30, 30 or 33 minutes la te r respectively. Two doses o f each 
opioid were studied and each in jection contained 7pCi o f ^H-labelled opioid.
4.5. Distribution Studies Protocol
A t times o f peak opioid antinociceptive a c tiv ity  (see Figure 2.1.) (also 1 hour 
a fte r DFP or saline adm inistration) animals were k illed by decapitation and 
trunk blood collected in to heparinised tubes. The brains were rapid ly 
removed and cooled over ice on a moistened f i l te r  paper covered pe tri dish. 
Brains were then dissected in to eight regions, fo llow ing a protocol s im ila r to 
tha t described by Glowinski and Iversen (1966). Each region was weighed and 
transferred to glass sc in tilla tion  vials to which 1ml o f Soluene-100 (Packard) 
was added. Plasma was obtained by centrifugation a t 2500g fo r 10 minutes 
and a 20pl o f plasma was solubilized w ith  0.5ml Soluene-100. Brains were le f t  
overnight to solubilize. With the larger brain regions, cerebellum and 
cortices, solubilization was promoted by warming the vials to 50°C fo r 10 to 
30 minutes, and allowing to cool.
4.6. Scintillation Counting
Follow ing solubilization, sc in tilla tion  flu id  consisting o f 1.5 litre s  o f sulphur- 
free toluene, 750ml o f synperonic NX PO POP 225mg and PPO 12g (Wood et
3
al, 1975) was added to samples. H a c tiv ity  was determined in an LKB 1210
U ltrobe ta  sc in tilla tion  counter. Chemiluminescence was avoided by
acid ify ing the sc in tillan t w ith  10ml glacia l acetic acid per 2.5 litre s  of 
sc in tillan t.
Presence of solubilised brain tissue has a quenching e ffe c t on detection of 
sc in tilla tions. As varying amounts o f brain tissue were present in each v ia l, 
i t  was im portant to take in to account and compensate fo r variable quenching. 
A quench correction curve was therefore set up. Brain tissue weighing 10, 20, 
40, 60, 80, 100 and 120pg were solubilized in 1ml o f Soluene-100. To each via l, 
10 pi o f hexadecane standard was added, and the vials counted on the 1210 
U ltrobeta . Decay tables fo r allowed to ta l a c tiv ity  per v ia l to be
calculated. With c.p.m. and R values from  these vials, the coe ffic ien ts  o f the 
data were calculated by applying a Basic regression programme (see Appendix 
D (i). This program yielded values fo r AO, A l, A2 and A3 which were 
programmed in to the sc in tilla tion  counter, enabling rad ioac tiv ity  to be given 
in d.p.m. The quench curve was also p lotted using the d.p.m. package on a 
RackBeta 1215 (see Appendix D (ii)).
A s im ilar procedure was carried out fo r plasma as occasionally samples were 
haemolysed. Plasma samples o f varying degree o f haemolysis were counted 
w ith  10pi hexadecane standard. The coeffic ien ts  were determined as fo r 
the brain samples.
RESULTS
4.7. Effect of DFP Pretreatment on Alfentanil Brain and Plasma Levels 
Figure 4.1. represents the e ffe c t of DFP on levels in various brain regions o f 
a lfen tan il, expressed in d.p.m ./g wet weight o f tissue.
P retreatm ent w ith  DFP at Img/kg caused a s ign ificant increase in the levels 
in a ll brain regions o f a lfen tan il at 400pg/kg (Figure 4.1.). This increase was 
most marked in the hypothalamus w ith  a 3.2-fo ld increase in levels compared 
to saline controls. There was a marked reduction in plasma a lfen tan il 
rad ioac tiv ity  (Table 4.1.). A t the 200pg/kg dose o f a lfen tan il, DFP appeared 
to l i t t le  a ffe c t brain levels. I f  brainrplasma ratios are considered (Table
4.2.), DFP pre-trea tm ent produced a s ign ificant e ffe c t in a ll brain regions 
and at both doses.
4.8. E ffect of DFP Pretreatment on Morphine and Fentanyl Brain and Plasma 
Levels
DFP appeared to have l i t t le  e ffe c t on brain levels o f fentanyl or morphine 
(Figure 4.2. and 4.3.). There was a slight decrease in morphine levels 
fo llow ing DFP but this only reached significance in the hypothalamus at the 
higher dose. S im ilarly, DFP did not s ign ifican tly  a lte r plasma ra d io a c tiv ity  
o f e ither morphine or fentanyl, (Table 4.1.) and so brain:plasma ra tios fo r 
these two opioids were very s im ilar in contro l- and DFP-treated animals 
(Table 4.2.).
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Plasma R ad ioactiv ity  
dpm m l" (x 10” )
Opioid
M orph ine, 
(10mg/kg~ )
Morphine 
(20mg/kg" )
Fentanyl , 
(40pg/kg" )
Contro l
197 - 7
118 - 10
7 3 - 7
DFP-Treated 
174 - 6 *
97 - 8
90 -13
Fentanyl , 
(80pg/kg” )
67 - 4 5 7 - 3
A lfe n ta n il . 
(200pg/kg )
166 - 10 110 ± 12*
A lfe n ta n il 
(400pg/kg" )
147 +34 9 1 - 6
Each value is the mean o f six observations, 
t  test, DFP vs. contro l *  p < 0.05
Table 4.1. E ffe c t of DFP (lm g/kg"^) on Plasma Levels 
o f H Morphine, Fentanyl and A lfe n ta n il
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DISCUSSION
4.9 Opioid Lipophilicity and Access to the CNS
Opioids exert the ir antinociceptive e ffe c t in the centra l nervous system. To 
gain access to the ir site o f action, opioids must cross the blood-brain barrier. 
Generally speaking, the greater the lip o p h ilic ity  o f an opioid (or any other 
drug) the greater the ease w ith  which i t  is able to cross this barrier and enter 
the brain (Jacobson, e t al, 1977).
A measure o f lip o p h ilic ity  is the octanohwater pa rtition  coe ffic ie n t at pH7.4 
and the lite ra tu re  values fo r the opioids studied are 1.42 fo r morphine 
(Kaufman et al, 1975), 130 and 860 fo r a lfen tan il and fentanyl respective ly 
(Meuldermans e t al, 1982). These values para lle l the order o f brain:plasma 
ratios obtained in this study. Levels o f rad io ac tiv ity  in the brain compared 
w ith  the plasma are highest fo r fentanyl, followed by a lfen tan il and then 
morphine. The times fo r measurement o f morphine, fentanyl and a lfen tan il 
levels were chosen to correspond to peak antinociception (see Section 2.6.). 
These times agree w ith  lite ra tu re  values fo r these opioids (Gardocki and 
Yelnoski, 1963; Johannesson and Becker, 1973). There is also a good
corre lation between levels o f these opioids in the brain and the ir
antinociceptive e ffects  (Johannesson and Becker, 1973; Hug and Murphy, 1981).
4.10. E ffect of DFP on Opioid Brain Levels
DFP pretreatm ent produced a disparate e ffe c t on the brain levels and
distribution of radiolabelled morphine, fentanyl and a lfen tan il. The most 
marked e ffe c t o f DFP is on the d istribution o f a lfen tan il where plasma levels 
are lower and at 400pg/kg a lfen tan il there is a concom itant rise in a lfen tan il
in the brain. This enhanced entry could account fo r the observed increase in 
the antinociceptive a c tiv ity  o f a lfen tan il fo llow ing DFP (see Section 2.24.). 
The absence of an apparent increase in brain levels o f a lfen tan il at 200pg/kg 
by. DFP may be partly  due to the decrease in plasma levels, since the blood 
present in the brain was not accounted fo r and contributes to the to ta l 
rad ioac tiv ity . A lte rna tive ly , DFP may be a ltering pharm acokinetic 
parameters so tha t peak brain a lfen tan il levels could occur earlie r. Peak 
opioid receptor occupancy or antinociceptive e ffe c t could persist fo r a short 
tim e a fte r peak drug level (see Figure 4.4.)
4.11. Mechanism of Increased Levels of Alfentanil Produced by DFP
There is no lite ra tu re  at present describing a potentia tion o f a lfen tan il by 
other drugs. However, there are some reports in the lite ra tu re  describing the 
action of some drugs in increasing the potency o f morphine by a mechanism 
o f increasing the plasma and brain levels o f this opioid. For example, a 
synergism has been demonstrated between diazepam and morphine (Sanchez 
et al, 1982). This appears to be dependent on diazepam com petitive ly  
inh ib iting morphine glucuronization and dem ethylation. This results in higher 
plasma and hence higher brain levels o f morphine. Brain uptake o f morphine 
was shown to be increased fo llow ing adm in istration of the antih istam ine 
tripelennam ine (Vadlamani, 1984) possibly by increasing perm eability o f the 
blood-brain barrier. By contrast, the potentia tion o f morphine by 
physostigmine did not appear to be dependent on a ltera tion in morphine 
plasma or brain levels (Bhargava and Way, 1972).
I t  is possible tha t DFP could increase a lfentan il's  entry into the brain also by 
a ffecting  the blood-brain barrier. Indeed, DFP has been shown to increase
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the perm eability  of capillaries in the anterior segment o f the eye (von 
Sallman and D illon, 1947). Furtherm ore, in considering the mechanism of 
potentia tion o f morphine antinociception by the two anticholinesterases, 
physostigmine and neostigmine, Rypka and N a vra til (1982) showed tha t the 
blood-brain barrier perm eability  to acridine orange was markedly increased 
fo llow ing adm in istration o f physostigmine and neostigmine. I f  however, DFP 
exerted this same e ffe c t on blood-brain barrier perm eability, this would be 
non-selective and i t  m ight be expected tha t a ll three opioids would a ll have 
enhanced entry in to the brain. Moreover, as a lfen tan il and fen tanyl are 
highly lip id  soluble, the blood-brain barrie r would not norm ally l im it  the entry 
of these drugs into the brain. On the other hand, the low lip id  so lub ility  o f 
morphine accounts fo r the low penetration o f morphine into the brain 
(H artv ig  et al, 1984). This means tha t an increase in the perm eability  o f the 
blood-brain barrier would tend to increase the entry o f a low perm eability  
agent such as morphine, ra ther than an agent which is highly lip id  permeable. 
The observation tha t morphine levels are unchanged by DFP tends to m ilita te  
against an action on blood-brain barrier perm eability  by DFP.
The evidence suggests tha t DFP enhancement o f a lfen tan il entry in to  the 
brain is probably more like ly  to be dependent on pre-blood-brain barrie r 
mechanisms. One such candidate fo r this mechanism is a lte ra tion  o f 
a lfen tan il binding to plasma proteins.
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5.1 Plasma Protein Bind[of Drugs
The a b ility  of plasma proteins to bind and transport chemicals and drugs has 
been known fo r many years (Rosenthal, 1926). The potentia l binding capacity 
is enormous w ith  an estimated to ta l surface area o f plasma proteins per 
person being between 130,000 and 735,000m (Bennhoid, 1967). In practice, 
only a frac tion  of this area is available as compounds tend to bind to specific 
sites (B ickel, 1978).
The binding o f drugs to plasma proteins has been comprehensively reviewed 
over the years (Goldstein, 1949; Meyer and Guttman, 1968; Jusko and Gretch, 
1976). I t  has become apparent tha t the protein binding o f a drug can 
influence its  d is tribu tion which d irec tly  and ind irec tly  influences the action 
o f the drug by determ ining its ava ilab ility  at its  sites o f action.
5.2 Plasma Protein Binding of AlfentaniljFentanyl and DFP
Studies in ra t, dog and man have shown tha t fentanyl and a lfen tan il have high 
frac tiona l binding to blood proteins (Meuldemans et al, 1982). As only free 
unbound drugs may cross the blood-brain barrier increased entry o f drug could 
occur if ,  fo r example, the proportion o f opioid bound to plasma proteins is 
altered fo llow ing DFP adm inistration. I t  is possible tha t DFP may a lte r 
binding of opioids to plasma proteins, as its adm inistration may produce 
e ither acidosis or alkalosis by e ither stim ulating respiration at high doses or 
depressing i t  at low doses (Karczmar, 1967) since fentanyl binding is markedly 
affected by a lterations in blood pH (Meuldermans et al, 1982). In addition, 
a lte ra tion  in pH would a lte r the per cent ionization (ionized drugs cannot pass
through the blood-brain barrier) and this could be im portant fo r fentanyl 
where only 9% is unionized at normal pH. Though a lfen tan il would be l i t t le  
a ffected as 89% is unionized, change in per cent ionization has been shown to 
markedly potentia te the brain uptake o f morphine as shown in a lka lo tic  rats 
(Schulman et al, 1984). However i t  appears tha t altered blood pH is not an 
im portant fac to r as o f the three opioids studied a lfen tan il pharmacokinetics 
are the most pH-independent.
DFP has also shown to bind, irrevers ib ly , to plasma proteins (Truhaut, 1966) 
and so i t  is worth enterta in ing the notion tha t DFP competes fo r or inhib its 
a lfen tan il binding, thereby increasing the proportion o f free a lfen tan il which 
is able to enter the brain. This form  of in te raction  is well known, and has 
also been shown fo r irreversib le anticholinesterase agents; i t  has been 
suggested tha t the potentia tion o f sodium pentobarbita l anaesthesia by soman 
is dependent on com petition fo r plasma protein binding (Clement, 1984). This 
mechanism of in teraction is considered in th is section.
5.3 Assessment of Drug Binding to Plasma Proteins
There are two main methods fo r determ ining free drug levels: equilibrium  
dialysis and u ltracen trifugation . Equilibrium  dialysis is the most used o f 
these methods but suffers from  a number of methodological drawbacks. 
These include Donnan effects, changes in ion concentration which may 
compete w ith  drugs fo r binding or a lte r protein conform ation (Bowers e t al,
1984). U ltra filtra t io n  has the advantage o f being a more rapid procedure 
though one drawback is tha t there may be non-specific adsorption o f drug to 
the u ltra filtra tio n  membrane (Zhirkov and P iotrovski, 1984), however th is 
adsorption may be determined and compensated fo r. I t  has been concluded
tha t ultracentrifuga'cion is a more sensitive method fo r determ ining small 
changes in protein binding (Coyle and Denson, 1984) and be tte r re flec ts  the 
real values than those obtained by equilibrium  dialysis (Tuila, 1984).
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Fig. 5.1. Protocol for Plasma Protein Binding 
Experiments Iri Vivo and Iri Vitro. 
(See text for details)
MATERIALS AND METHODS
5 .4 Animal and Experimental Conditions
Male albino mice (CD-I strain; 25-30g) were used as described in Section 
2.2.1. Procedures fo r equ ilibration were also as those previously described.
5.5 Drugs
The drugs used were obtained from  sources described in Section 2.6. and 4.6. 
5.6. In Vivo Protein Binding Protocol
Timings o f drug adm inistrations were the same as the previous experiments
(Section 4.4) where DFP or 0.9% w /v saline was given s.c. at tim e 0, fen tanyl
(80pg/kg) at 50 minutes, and a lfen tan il (400pg/kg) was administered at 55 
minutes. Each in jection contained 7pCi o f opioid. Trunk blood was 
collected fo llow ing decapitation at 60 minutes, and plasma obtained by 
centrifugation, (Fig 5.1.).
5.7 In Vitro Protein Binding Protocol
Mice received s.c. DFP or 0.9% w /v saline and were sacrificed by 
decapitation 60 minutes la te r. A 250pl a liquot of plasma obtained fo llow ing 
centrifugation was incubated fo r 30 minutes at 37°C w ith  25pl ^ H a lfen tan il 
or ^ H fentanyl. The incubation medium contained additional cold opioid so 
tha t drug concentrations paralleled those fo llow ing a s.c. antinociceptive 
dose (Fig 5.1.).
5.8. Ultracentrifugation Protocol
Free drug concentrations were determined by u ltracen trifuga tion  o f plasma 
samples in an Amicon m icropartition  MPS-1 k it  (Figure 5.2.). A 200pl aliquot 
was pipetted in to the sample reservoir o f the assembled unit. The un it was 
centrifuged in a bench top centrifuge at 1500g fo r 10 minutes. A 20pi a liquot 
o f the u ltra f ilt ra te  (i.e. unbound drug) and 20p i o f the plasma (i.e. to ta l drug) 
were added to polythene tubes in duplicate. 3-5mls o f Unisolve-1 sc in tilla tio n  
flu id  (Koch L ight) was added and tubes were counted in a RackBeta 1215 or 
1216.
5.9. Calculation of Free and Bound Drug Concentration
Calculation o f the free and bound drug concentrations were made from  data 
o f u ltra f ilt ra te  and plasma rad ioactiv ities  using the equation:
Total drug concentration = bound concentration + Free concentration 
Plasma Concentration)
So, % Bound = Total - Free 
100
or % Bound = 100 - % Free
5.10. Determination of Drug Adsorption in Ultracentrifugation Apparatus
Recovery experiments were performed to determine whether any loss o f 
a lfen tan il or fentanyl occurred during the u ltracen trifuga tion  process through
adsorption on the membrane or plastic reservoir. A stock of mouse plasma
3 3contaimrKj e ither H a lfen tan il or H fentanyl was aliquoted and
ultracentrifuged as described in Section 5.6. R ad ioactiv ity  was determ ined
fo r the stock and fo r u ltra f iltra te s  in duplicates. Recovery could then be 
determined by comparing rad ioactiv ities  in the original stock w ith  the 
u ltra f ilt ra te .
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RESULTS
5.11. Recovery Experiments
Recovery experiments fo r a lfen tan il and fentanyl showed tha t the a lfen tan il 
u ltra f ilt ra te  contained 103 - 11% (n=4) o f the orig inal stock and the fentanyl 
u ltra f ilt ra te  contained 80.7 - 1.3% (n=6).
5.12. Percentage of Plasma Protein Binding of Fentanyl and Alfentanil
Contro l binding o f a lfen tan il were fa ir ly  s im ilar fo llow ing in vivo and in v itro  
binding protocols (Table 5.1). The figures fo r fentanyl binding in contro l mice 
were quite d iffe ren t, dependent on whether _in vivo or in v itro  protocols were 
used.
5.13. Effect of DFP on Binding Fentanyl and Alfentanil to Plasma Proteins 
Table 5.1. shows the e ffe c t o f DFP (lmg/kg) on the levels o f plasma to ta l and 
plasma free a lfen tan il and fentanyl fo llow ing incubation in v itro . The values 
presented have been adjusted fo r losses during u ltracen trifuga tion  in the in 
v itro  experiments. There was no a ltera tion in free or bound fentanyl in the 
presence o f DFP (Table 5.2.), however, there was a greater than 40% increase 
in free a lfen tan il in DFP treated plasma.
The e ffe c t o f DFP on m vivo adm inistration o f a lfen tan il (Table 5.2.) is more 
marked w ith  nearly a 60% increase in free a lfen tan il. For in vivo binding of 
fentanyl, DFP has very l i t t le  e ffe c t on free levels (Table 5.2.)
Table 5.1.
Treatment
Saline
DFP
Img/kg
Effect of DFP Treatment on In Vivo and In Vitro 
Plasma Levels of Alfentanil 
and fentanyl
Alfentanil
ng/ml
In vivo
Fentanil
ng/ml
In v itro  In v itro
in vivo
Tota l 485 - 25.2 519 - 5 16.87^0.36 13.25 - 0.76
Free 118 - 6.1 140 ± 10 2.01 - 0.14 7.09 - 0.54
Total 286 - 40.2 517 - 9 16.30 - 0.59 12.25 - 1.51
Free 110 - 13.0 195 - 12 1.83 - 0.06 5.63 - 0.68
Values are means ^ SEM of 6 observations.
Table 5.2. E ffect of DFP Treatment on Levels of In Vivo and in Vitro  
Free Plasma Levels of Alfentanil and Fentanyl
% Free levels
Treatment Alfentanil Fentanyl
In V itro  In Vivo In V itro  In Vivo
Saline 24.3 26.9 53.5 11.9
DFP lm g/kg 38.5 37.8 46.0 11.2
DISCUSSION
5.14 DFP Binding to Plasma Proteins
DFP is known to bind plasma proteins in several species including man 
(Jandoff and McNamara, 1950; Cohen and Warringa, 1954; Murachi, 1963; 
Truhaut, 1966; Ramachandran, 1967; Hansen et al, 1968; Schuh, 1970; M artin , 
1985). DFP is capable o f combining covalently w ith  most proteins (M artin , 
1985) in a general type o f a lky l phosphorylation reaction (Murachi, 1963; see 
Figure 5.3.). The percentage of DFP bound to plasma proteins is high 
fo llow ing in jection; a dose o f lm g/kg DFP i.v . in mice results in over 95% o f 
plasma DFP being bound.
There has been l i t t le  work on a ttem pting to iden tify  to which protein DFP is 
bound. Schuh (1970) however, has indicated that albumin is the main prote in 
as the same values fo r percentage DFP binding can be obtained by 
substituting a 3.2% albumin solution, equivalent to normal plasma 
concentrations.
5.15. Plasma Protein Binding of Alfentanil and Fentanyl
Both a lfen tan il and fentanyl have been shown to have high frac tiona l prote in 
binding (Meuldemans et al, 1982). The results in this thesis showing around 
75% binding fo r a lfen tan il are consistent w ith  those obtained in the 
lite ra tu re : fo r ra t, dog and man and the fraction  bound is 84, 73 and 92% 
respectively (Meuldermans, et al. 1982). Values obtained in this thesis fo r 
fentanyl binding vary depending on the method used. Follow ing in v itro  
methodology, fentanyl binding was found to be sim ilar to that obtained in ra t,
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dog and man (Meuldermans, et al, 1982). In vivo binding yields a lower 
percentage level which is sim ilar to tha t obtained by Murphy et al (1979) in 
the dog. The discrepancy observed in the study presented here between jn  
vivo and jn  v itro  binding could depend on several factors; fentanyl binding is 
temperature and pH dependent (H o llt and Teschemacher, 1975) so tha t change 
from  pH 7.4 to pH 7.55 increases fentanyl binding from  67% to 76%. The 
37°C incubation step in the in v itro  binding protocol could produce the 
observed increase in fentanyl binding compared to the in vivo protocol.
Though s truc tu ra lly  s im ilar, these drugs do not apparently bind to the. same 
sites. Fentanyl has been shown to bind red blood cells, glycoproteins and 
lipoproteins, w h ilst a lfen tan il is predominantly bound to the acute phase 
reactant protein a^-acid glycoprotein (a^-AGP) (Meuldemans et al, 1982). In 
fac t, Meuldemans et al (1982) have calculated tha t i f  a^-AGP were the only 
binding protein, i t  could account fo r a ll a lfen tan il binding in human
plasma but only about ha lf of fentanyl binding. Volunteer plasma samples 
showed a linear relationship between a^-AGP concentration and free drug 
frac tion  only fo r a lfen tan il (Meuldermans et al, 1982).
5.16. E ffect of DFP on Plasma Protein Binding of Alfentanil
The presence o f DFP decreased the frac tiona l binding o f a lfen tan il to plasma 
proteins. As a lfen tan il is highly lipoph ilic , the blood-brain barrier does not 
l im it  the entry o f free a lfen tan il into the brain. I t  is reasonable to suppose, 
therefore, tha t by increasing free a lfen tan il increased brain levels and 
increased antinociceptive e ffe c t would fo llow . DFP did not a lte r fentanyl 
plasma protein binding and so an explanation fo r the observation o f 
d iffe re n tia l potentia tion by DFP o f a lfen tan il antinociception could be made 
on the basis of DFP specifica lly  inh ib iting the binding o f a lfen tan il to plasma 
proteins.
Though Schuh (1970) suggested that DFP binds to albumin (see Section 5.12.), 
this does not rule out the possib ility that DFP also binds a^-AGP because as 
already mentioned, DFP reacts w ith  most proteins and w ill phosphorylate 
several classes o f proteins when incubated w ith  plasma in v itro  (Murachi, 
1963).
Moreover, i t  has been recently shown that albumin potentiates the binding o f 
propanolol to a^-AGP (Chauvelot-Moachon e t al, 1985) so tha t i f  this held 
true fo r a lfen tan il, binding to a^-AGP could be a ffected by DFP 
phosphorylation o f albumin.
a-^-AGP is a high a ff in ity  low capacity binding protein (Piafsky, 1981; 
Mackichan and Zola, 1982), so that i f  DFP were to compete fo r and saturate 
binding sites on the a-^-AGP molecule this would lead to raised levels o f free 
a lfen tan il. Fentanyl, on the other hand, i f  displaced from  these sites, would 
not necessarily result in increased free levels as i t  could be sequestered in 
other high capacity binding depots such as red blood cells.
Several drugs have been shown to bind a-^-AGP and there is often a m utual 
displacement o f drugs as there is only a single binding site (MUller e t al, 1983). 
Furthermore, the binding site m ight represent a remote hydrophobic area 
w ith in  the protein part of the glycoprotein molecule (Brunnmer and MUller,
1985). So not only is the binding site probably a protein to which DFP could 
covalently bind, but i t  is also a hydrophobic region where the DFP molecule 
would tend to go due to its lipoph ilic  nature (Karczmar, 1967). There is a 
good corre lation between displacing potency against ^ H -im ipram ine from  
a^-AGP and lipoph ilic  parameters for a varie ty  o f compounds (MUller et a l,
1983).
5.17. Consequences of Alfentanil Displacement from Plasma Protein
Binding Sites
As the e ffe c t o f a drug appears to be more closely related to the free 
unbound levels rather than the to ta l concentration (Lima et al, 1981) the 
question arises as to what the consequences o f the displacement o f bound 
a lfen tan il by DFP.
The degree of prote in binding o f a lfen tan il lim its  its  entry in to the brain. 
This is re flected  in the brainrplasma ratios which average about 0.6 at 
400ug/kg (see Table 4.2.). L ite ra tu re  values measuring unchanged a lfen tan il 
ra ther than to ta l rad io ac tiv ity  show braintplasma ratios averaging around 0.13 
in the ra t fo r 10 minutes fo llow ing i.v. adm in istration (Michaels et a l, 1981).
I f  binding to plasma proteins lim its  a lfen tan il entry in to the brain, 
displacement by DFP would tend to cause a proportional increase in entry o f 
a lfen tan il. In this situation, displacement o f a lfen tan il would not a lte r the 
average free drug concentration, though there would be a transient rise in 
free drug concentration im m ediate ly fo llow ing displacement (Mackichan,
1984). This is borne out in the data presented in Table 5.1. fo llow ing in vivo 
binding as free drug concentrations were l i t t le  changed. The jn  v itro  binding 
data shows tha t DFP increases free a lfen tan il concentrations. In vivo this 
free a lfen tan il is able to red istribu te  in to other tissues including the brain, so 
tha t the actual steady state concentration is not altered jn  vivo fo llow ing 
DFP whilst the average to ta l drug concentration decreases.
5.18. Protein Binding and Relationship to Variation in Alfentanil Potency
As described in Section 2.27. in it ia l studies w ith  a lfen tan il showed AD^g 
values d iffe ren t from  tha t obtained in experiments some months la te r. One 
explanation fo r this anomaly was that there is a varia tion in circannual 
sens itiv ity  to a lfen tan il, however, though this may be true, the data from  the 
binding experiments which show the relevance o f a lfen tan il binding to its  
potency, introduces the possibility tha t varia tion in binding could markedly 
a ffe c t potency. If, fo r example, the batch of mice in the in it ia l experiments 
were carried out had a low level v ira l in fection, this could greatly increase 
a^-AGP levels and hence binding capacity. This could e ffe c tive ly  increase 
the true AD^-g value.
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6 GENERAL DISCUSSION
In the foregoing chapters an account has been given o f the potentia tion  of 
a lfen tan il, but not morphine or fentanyl antinociception by DFP pre-trea tm ent in 
mice. This e ffe c t was not reversed by drugs used to tre a t DFP poisoning. In 
addition, DFP has d iffe re n tia l e ffec ts  on opioid-induced running behaviour, w ith  
the most marked e ffe c t observed in a lfen tan il-trea ted  mice. Further 
experiments identified  tha t DFP enhanced the entry o f a lfen tan il in to the brain, 
w h ils t the d istribu tion o f the other opioids was unaffected. This appeared to be 
due to a displacement o f a lfen tan il from  plasma protein binding sites, thereby 
allowing more drug to enter the centra l nervous system.
The d iffe re n tia l potentia tion o f a lfen tan il may w e ll be dependent on the 
observation tha t this opioid p rim arily  binds to a^-AGP w hils t fentanyl binds 
more than one protein (Meuldermans et al, 1982). Morphine's low frac tio na l 
binding means tha t displacement from  these sites would not greatly  increase free 
drugs.
There are im portant im plications to the findings presented here, demonstrating 
functiona l increase in antinociceptive potency o f a lfen tan il fo llow ing 
displacement from  its plasma protein binding sites. In these studies, the data 
shows that in mice, 75% of a lfen tan il is bound to plasma protein, w h ils t in 
humans the figure is 92% bound (Meuldemans et al, 1982). The higher the 
frac tiona l binding the greater the percentage increase in free drug fo llow ing 
displacement, thus in humans, potentia tion o f a lfen tan il action could be even 
greater than that observed in mice.
A lfe n ta n il binding may vary in patients i f  they are not receiving any drug 
therapy, as the normal levels o f a^-AGP varies in normal healthy volunteers 
from  55 to 140mg/100ml w ith  a mean of 66mg/100ml (Piafsky et al, 1978). 
Increased levels are probably due to subclin ical or m inor in fections. a^-AGP 
levels are also increased as a result o f the physiological stress associated w ith  
in flam m ation, cancer (Piafsky, 1980) and surgery (Fremsted e t al, 1978).
This in form ation suggests tha t a lfen tan il potency may be sensitive to 
pharmacological and physiological variables, which may be im portan t c lin ica lly . 
I t  should be borne in mind, however, tha t i t  is an assumption to extrapolate the 
demonstrated in teraction in an experimental animal to an in te raction  in humans. 
An assessment o f the potentia l in teractions of a lfen tan il w ith  other drugs should 
therefore be carried out w ith  other drugs and using human plasma.
The property o f the potentia ting a c tiv ity  o f DFP does not appear to be 
dependent on its  anticholinesterase a c tiv ity  per se, as the carbamate 
anticholinesterases neostigmine and pyridostigm ine, did not a lte r a lfen tan il 
antinociception. A plausible in te rpre ta tion  o f th is is tha t DFP may produce a 
stable phosphorylated plasma protein (which competes fo r a lfen tan il binding) and 
this may hold true fo r other organophosphorous compounds including 
organophosphates. Given tha t in DFP treated mice, morphine antinociception is 
altered fo llow ing atropine and pralidoxime adm in istration, fentanyl appears to  be 
the opioid of choice and the least like ly  to cause in te raction  problems w ith  
organophosphates or drugs used in the trea tm ent o f anticholinesterase poisoning.
This study has shown the existance and probable mechanisms of DFP potentia tion 
o f a lfen tan il antinociception. This is of importance not only as an example o f 
the relevance of plasma protein binding on drug e ffe c t, but also in term s of the 
possible im plications fo r the c lin ica l use o f a lfen tan il fo llow ing adm in istra tion o f 
other drugs. There is clearly scope fo r fu rthe r research in this area.
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Equation for Unpaired Student’s t-test
t = x
(SEM^2 + (SEM2)2
APPENDIX B
C om puter P rogram  fo r A n tin o c ice p tive  D ata  in Mouse H o t-P la te  Test
A set o f data has th ree  components, the mean response tim e , the va ria tio n  o f 
response tim e  about the mean, and the e rro r d is tr ib u tio n . For th is  data, i t  
was found th a t a W eibu ll d is tr ib u tio n  could successfu lly be applied to  th is  la s t 
com ponent. The data may also be lin e a rlize d , such th a t log (mean response 
tim e ) is linea r in dose. S tra ig h t- lin e  regression is ca lcu la ted  by a m ethod 
s im ila r to the usual least-squares method, using a general procedure ca lled  
m axim um  like lihood  es tim a tion . The sum o f squares is rep laced by the 
like lihood  fun c tio n , which represents the p ro b a b ility  o f obta in ing  data under 
the model. This model enables p red ic tions  to  be made on the percentage o f 
response tim es th a t exceed 60 seconds. This model also a llows fo r  the 
inclusion o f zero-dose (ie, saline) data. A fu lle r  descrip tion  o f th is  m odel is 
given by K itchen  and C row der (1985).
A N A lG fM  SCREEN i;A T A  FEB S 3 ) :  CENSORED RESPONSE H U E S  UNDER DRUGS
ANA < O LS U . • >: REFN DATA <FF.R 6 3  M  CENSORED RESPONSE T IM E S  ..»NOEP DRUGS 
REAL XS ( .0 >. 1 0 ) .  WX C c»X ; .WY< 6 0 0 >  . R ( 1 5 )  . B L U ( 2 . 1 5 /
DOUBLE PRF.C I S IO N  WI ( I 5  / . W 2( 1 5 )  , W 3(1  5 .  1 5  ) . P I  V ,T G L .L L K D  
COMMON -'R ID A T  /  Y < 6 0 0  > . N . YMS . VCNSR. X ( 6 0 0 .  10 > . NDRG 
EXTERNAL C R T0 12
DATA IX / 6 0 0 .  . I W / T O C / I  . D - 1 0 /
READ C.AfA E T C .
READ; 1 . *  > I RF>. Iw R , I  CHECK 
10 C ALL I k R T O l( IR D . IC H E C K )
Z F ( N . lE . O )  STOP 
20  UR IT E M  i PC-1)
R E A D H . * )  NO
I E <N O .L E . 0 )  GOTO tO
MLE F I T  BY T R IA L  AND ERROR
N P -N P R O +2
I F ( N P . 0 T . I 5 >  STOPno so j«i , is
Rl.U< 1 , J ) = 0 .
3 0  D L U (2 .* J )  = 1 0 0 .
B L U M .  N P > * . 01 -
C A L L  F M IN !C R T 0 1 2 .N P .W 1 ,L L K D » W 2 .W 3 .W 3 ,IW .B L U )  
r  PARAMETER C O VARIAN C E M ATR IX
A - W K 1 )
DO 5 0  J s l .N D R G  
5 0  B < J ) * W 1 ( J * l >
G AM =W 1(NP)
W R IT E (1 .9 0 © )
R EAD ( I . *  > IC O V
IF < IC O V . N E .1 )  GOTO 7 0
W R IT E ( IW R .9 0 2 )  (W 1 ! J ) , J = 1 »N P ) , LL K D
C A L L  C R T 0 0 2 ( A .B »  G A M .L L K D .W 1 . W 3 » IW .2 . 1 )
DO 5 5  J = 1 ,N P
C A LL M X S W P 0 (W 3 .IW ■NP * N P »U »P I V » T G L )
5 5  W RITE< 1 ,9 0 .3 )  J . P I V  
DO 6 0  J - l . N P  
U 1 ( J ) * - W 3 ! J , J )
IF ( W 1 ( J ) . G T . O . ) W 1 ( J )= D S Q R T ( W 1 (J ) )
6 0  C O N TIN UE
W R I T E M . 9 0 7 )  (W1 ( J ) . J « I , N P )
W R IT E ! IW R .9 0 8 )
DO 6 5  J * l . N P  
6 5  W R IT E !IW R ,S 0 2 T  <U 3 < J . K ) . K = l . U )
W R IT E M W R .9 0 6 )
DO 6 7  J = 1 • NDRG 
E D 1 - . 6 9 3 1 5 / B ! J )
E D 2 - ( 3 . 4 0 1 2 0 - A ) / B ( J )
S D I» E D 1 * W 1 ( J + l ) / B ( J )
S 0 2 —  < W 3( 1 . 1 ) * 2 . «E D 2« W 3( 1 . J + l ) + E 0 2 *E D 2 *W 3 ( J + l . J + 1 ) )  
t F ( S D 2 . G T . O . ) S D 2 -S Q R T ( S D 2 ) /B ( J >
6 7  W R IT E !IW R ,8 0 2 )  E D I* S D 1 . E D 2 .S D 2  
C R E S ID U A LS
7 0  W R IT E !1 . 9 0 9 )
R E A D M .* )  IR E S
I F ! I R E S . E Q . 1 )  C A L L  C R T 0 2 2 !A .B .G A M .W Y ,IW R )
GOTO 2 0
8 0 1  FOR M AT( 2 0 1 4 )
8 0 2  FO R M A T (1 P 8 G 10 . 3 )
9 0 ?  F O R M A T !/IO H P A R A M E T E R S /!1 P 6 G 1 2 .5 ) )
9 0 3  F O R M A T (5 H P IV 0 T . 1 2 . IP G 1 0 . 3 )
9 0 4  FORM AT( /4 5 H F I T :  ORDER OF REGN ( l- L IN E A R .2 -Q U A D R A T IC .E T C ) )
9 0 6  F O R M A T (/4 H E D 5 0 )
9 0 7  F O R M A T !/1 0 H S T D  E R R O R S / !1 P 8 0 I0 .3 ) >
9 0 3  F O R M A T !/27H P A R A M E TE R  C O VA RIAN C E M A T R IX )
9 0 9  F O R M A T (/9 H R E S ID U A L S )
END
SU BR O U TIN E IK R T 0 1 ( IR D .IW R )
C A N A L G E S IC  SCREEN CENSORED RESPONSE T IM E  DATA (F E B  8 3 )
C X HAS COLS (DRUG NO. . D O SE. RESPONSE T IM E )
IN TEG E R  N O ( 2 0 )
R EAL D S ( 2 0 )
C O M M O N /R TD A T /Y ( 6 0 0 ) >  N .Y M S . YCNSR, X ( 6 0 0 . 1 0 ) . NDRG 
YUS— 9 9 .
Y C N S R -6 0 .
D 0 S D IV - 1 0 0 .
N * 0
R E A D !IR D ,8 0 3 )  NDRG
IF ( N D R G .L E .0 )  RETURN
DO 3 0  J D R G - l . NDRG
R EAD ( IR D .8 0 4 )  NDS
READ < IR D . * )  ( D S ( J ) . J - 1 . N D S)
R E A D M R O .* )  ( N D ( .J ) , J * 1  .N D S )
IF ! I W R .G T .O )  W R IT E !IW R ,8 0 2 )  ( D S ! J ) , J « 1 . N D S )
1 1-N-* 1
DO 2 0  J - l . N D S  
N J - N D ( J )
DO 2 0  I - l . N J  
N -N M
X ! N . 1 >*UDRG 
20  X ( N ,? ) - n S ! . J ) /D O S D IV
R E A D !IR D .# )  ! X ( I * 3 ) . I - I 1 * N >
30 C i-in T IN IIF
VC N SR -ALO G ( YCNSR>
DO 4 0  1 = 1 ,N  
Y I  = X < 1 .3 )
I F !  V I . G T . O. ) Y ( I ) = 01 .00 ( Y I  5 
4 0  CONTINUE
I F ! I W R . L E . 0 )  RETURN 
W R IT E !IW R ,9 0 1 >
DO 6 0  1 - 1 . N 
6 0  W R IT F !IW R .8 0 ? >  r X ( I ,..»> . J =  1 ..? ) , Y ! I >
RETURN
8 0 2  FORM AT( 1 P 8 G 1 0 . 3■
8 0 3  F O R M A T !5 X .1 3 )
8 0 4  F O R M A T (J5 X . 13.)
9 0 )  F O R M A T !/1 0 H 0 H F C K  D ATA)
END
SU BR O U TIN E C R T0 12 < N P .P A R ,F N , G R ,H . IH , I G R . IW R )
T  P A R !. ) *A »  B ( D  . . . . , B (N D R G ). GAM
R EAL B ( 1 5 )
DOUBLE P R E C IS IO N  F N ,P A R !N P ) . G R (N P ) . H ( I H . I H )
C O M M O N /R TD A T /Y ! 6 0 0 ) .N .Y M S ,Y C N S R ,X ( 6 0 0 ,1 0 ) .NDRG 
A = P A R (1)
DO 2 0  J * I ,N D R G  
20 B ! J ) * P A R ( J + l )
0A M =PAR !N P1
CAL t. C R TO O ruA . B .G A M .F N .G R .H . IH ,  I  OR, IW R)
RETJIRN 
END
t  IN S E R T  IK 'CRTB 
* IN S E R T  FMTNP
SUBROUTINE CRT002 <A,B.GAM.LLKD, Gl.»HL , IH, IGR, IWR)
SUBROUT IN E  C R T 0 0 2 !A .6 , G A M .L L K D ,G L »H L , IH , IG R , IW R )
M IN U S  L O G -L IK D  AND D E R IV S  TOR L O G -W E IB U LL  CENSORED RESPONSE T IM E S  
f. M U /S IG  MODEL S U P P L IE D  BY S /R T N E  C R T0 03
REAL MU, B ! 1 5 )»  GP ! 2 ) .  GC ! 2  ) » H P ! 2» 2 ) » H C ! 2» 2  ) .  GM! J 3  ) •  O S ! 1 5 )»
1 H M <1 5 . 1 5 ) , H S ( 1 5 .1 5 )
DOUBLE P R E C IS IO N  L L K D ,G L ( I H ) , H L ( I H , I H )
C 0 M M O N /R T D A T /Y I6 O 0 ) ,N .Y M S .Y C N S R ,X I6 0 0 ,1 0 ) .NDRG 
L L K D * 0 .
N P -N D R G + 2 
I F ( N P , G T . 1 5 )  STOP 
IF  { IG R . I .E . 0  > GOTO 2 0  
DO 15  J * 1 , NP 
G I „ ! J > * 0 .
I F ( I G R . L E . l )  GOTO 15 
DO 1 0  K = 1 ,N P  
1 0  H L ( J . K ) = 0 .
15  C O N TIN UE 
2 0  DO 4 0  1 *1  ,N  
Y I * Y ! I )
IF ! Y I , F J 3 .  YMS) GOTO 4 0  
I D * I F I X ! X ! T » l ) + . 5 >
D S * X ( 1 , 2 )
C A L L  C R T 0 0 3 ( A , B . NDRG. GAM, ID .D S .M U .S IG .G M .G S .H M .H S ,1 5 . IG R )
IF IY I . L T . Y C N S R )  C A L L  W B L L 0 1 < Y I, M U ,S IG ,P D .C O ,G P .G C ,H P .H C .IG R )
IF IY I .G E .Y C N S R )  C A L L  W B L L 0 1 < Y I, M U ,S IG .C D .P D ,G C ,G P .H C .H P ,IG R )
I.L K D *L L K D --P D
I F ( I G R . L E . O )  GOTO 4 0
DO 3 5  J * 1 .N P
I F ! I G R . L E . 1 )  GOTO 3 5
DO 3 0  K *  I , J
H t L t , K ) * H L ! J . K ) - ! H P ! l . l ) # G M ! J ) + H P < t » 2 ) # G S ! J ) >*G M !K )-G P < 1 ) * H H < J ,K ) -  
1 ( H P ( 1 , 2 ) « G M ! J ) + H P ! 2 . 2 ) * G S ! J ) > * G S ! K ) - G P ! 2 ) # H S ! J . K >
3 0  H L ( K . J ) * H L ( J . K )
3 5  G L ! J )  *G L .! J )  - G P ! t ) « G M !U ) - G P !2 ) * G S < J )
4 0  C O N TIN U E
IF ( IW R .L E . O )  RETURN 
W R ITE  < IWR * 9 0 1 )
W R IT E ! IW R .8 0 3 )  LLK D
W R IT E ! IW R .8 0 2 )  ! G L ! J ) » J * 1 . N P )
DO 5 0  J * 1 * NP 
5 0  W R IT E !T W R .8 0 2 )  ! H L ! J . K ) . K « 1 . J>
RETURN
8 0 1  F O R M A T !2 0 I4 )
8 0 2  F O R M A T !1P 8G 10 . 3 )
8 0 3  F O R M A T !IP G 1 2 . 5 )
9 0 1  F O R M A T !/2 5 H M IN U S  L O G -L IK D  AND D E R IV S )
9 0 6  F O R M A T !2 I 3 .1 P 6 G 1 2 .5 / ! 6 X ,1 P 6 G 1 2 .5 ) )
END
S U BR O U TIN E C R T 0 0 3 ! A , B »N B • GAM, ID ,D S ,M U .S IG ,G M ,O S .H M .H S ,IH . IG R )
C CENSORED RESPONSE T IM E S
C REGN MODEL TYP E M U - A + B ! ID ) * D S  !FO R  DRUG ID ,D O S E  D S ) ,  SIG *O AM »M U
C RETURN  M U ,S IG  AND D E R IV S  WRT < A ,B ( . )» G A M )
R EAL 8 ! N B ) . M U . G M ! I H ) , G S ( I H ) , H M ! I H , I H ) , H S ( I H , I H )
B D * B ! ID ) « D S
M U *A+BD
S IG -G A M *M U
I F ! I G R . L E . 0 )  RETURN
N P »N B -f2
DO 2 0  J - 1 , NP
C M ! J ) * 0 .
2 0  G S ! . J ) * 0 .
G M (1 ) * 1 .
G M !ID + 1 ) * D S  
O S ( 1 ) *GAM 
G S (ID + 1 ) *G A M * D S  
O S ! N P ) *M U
I F ! I G R . L E . 1> RETURN 
HS i  1 ,  N P ) *  1 .
H S 1 N P ,1 ) * I .
H S ! ID + 1 »NP)«=DS 
H S 1 N P ,ID + 1 ) * D S  
RETURN 
END
S U D R O U TIN E C R T 0 2 2 !A ,B ,G A M .O R » IW R )
C 1 0 G -W E IB U L L  CENSORED RESPONSE T IM E S ! E X P O N E N TIA L R E S ID U A LS
C O R ! 1 ) , , . . . O R !N ) CORRESP TO NON-CENSORED Y 'S
IN TEG E R  NW! 6 0 0 )
R E A L M U , B ( 1 5 ) » O R !6 0 0 ) ,G M !1 > . O S !1 ) ,H M !1 , 1 ) , H S !1 » 1 )
C O M M O N /R TD A T /Y ! 6 0 0 ) . N ,Y M S , YCNSR. X ! 6 0 0 , 1 0 ) , NDRG 
D ATA E G /O .5 7 7 2 1 5 6 6 4 ? / . P 6 / 1 .2 8 2 5 4 9 8 /
I F ! IW R .G T .0 )  W R IT E !IW R ,9 0 1 )  N ,N D R G .Y M S .Y C N S R
DO 2 0  1 * 1 . N
I D * I F I X ( X ! t . t ) + . 5 >
D S - X ! 1 , 2 )
C A L L  C R T 0 0 3 !A .B .N D R G ,G A M . ID ,D S .M U ,S IG ,C M .O S .H M ,H S ,1 . 0 )
Y D * P 6 « ! Y ! I ) - M U ) /S I G  
O R !I> * E X P !Y O - E G )
I F ! I W R . G T . 0 )  W R IT E !IW R .8 0 3 )  I D , D S . M U . Y ! I ) . Y D ,O R ! I )
7.0 C O N TIN UE 
RETURN 
8 0 3  FORM AT! I 3 . 9 F 8 . 4 )
9 0 1  FO R M A T !/ ? ! H E X P O N EN TIAL R E S ID U A L S .2 1 4 , F 6 . 1 . F 7 . 4 )
END
SU BR O U TIN E W Bt.LO l ( Y ,M U . S IG ,P P .  CD, G P ,G C , H P . HC, IG R )
C LO G -W E ID U L L D IS T N : P D -LO G  D E N S IT Y  F N , C D *l O G !1 -D IS T N  F N ) .  AND
r  D E R IV S  WRT M U ,S IG
R FAL M U ,G P !2 ) , G C ! 2 ) . H P !2 , 2 ) . H C ( 2 . 2 )
DATA E G /O .5 7 7 2 1 5 6 6 4 9 / . P 6 / 1 . 2 8 2 5 4 9 8 /
Y D = P 6 * ! Y - M U ) /S IG  
E Y *E X P (Y P -E G )
P D *A LO G ! P 6 /S I G ) + Y D -E G -E Y  
C D *-E Y
I F !  IG R . L E . 0 )  RETltRN
G P !1 ) * - P 6 * ! 1 . - E Y ) / S I G
0 P ! 2 > * - ! ! . + Y 0 * ! 1 . - E Y > ) /S IG
G C !1 > *P 6 « E Y /S IG
G C !2 > * Y D « E Y /S IG
I F ! I G R . L E . t )  RETURN
S 0 2 * S IG * S IG
H P ! 1 , I> * - P 6 * P 6 * E Y / S 0 2
H P ! I , 2 ) * P 6 + ! 1 . - E Y -Y P # E Y ) / $G 2
H P !2 » 1 ) « H P !1 , 2 )
H P ! 2 , 2 ) * ! 1 . + ! Y D + Y D ) * ! 1 . —E Y ) -Y D * Y D * E Y ) /S G 2
H C ( 1 . 1 )» - P 6 * P 6 * E Y /S G 2
H C !1 . 2 ) = - P 6 * ( 1 . + Y D )+ E Y /S G 2
M C ! 2 , 1 ) * H C ! J , 2 )
H C !2 »  2 ) * - ! 2 . + Y D > » F Y *Y D /S G 2
RETURN
END
i
S S
5 C Sc
MM I !si& N :5ts:& » 5*. t -  £5• > -  > «* > •  -0710- •  • •  -O* -
-
□ 5 S 
£ £ £
h si s i l l  7 - i  7
• i *
' .Z 2
: ^ s «
2 < < £
< 5 5 - 5Sls:;‘=us
i s r ill! lllfl^ lls
s l b s Isslst Isslllsslls il.J l| Slil
E
p P
0 Op -P
0 O
Q s
0
0 0
p> 0
1—1
TJ
0 d
CQ
P >£ P
-p •H
S *Ha5 p> mP -H pbe p> 0
0 0 m
P c pf t 0
p CQ
p 0
0  +J T5
+J 0 0
P s P
P: O d
E O P
O O «H
O  ftl p
•H
a il |a 2 ‘i|!|2Si«i??2«ssr !»»*■, iiiin i^ iiii  m u  llllfllllll*
cp
o
I ;  H  n  t 111) •; |"‘ <EW * ^  3 c -£ <«« << rr
£ r  « 5 5 5 B " u i ^ u l y o c u o | S ? ; ; « c .  55?l 5 M M! s„  r=s * : 66
l l j  ! s l i ! J s | ^ ! P ! f *!f*! ” -
= = E s i * f l ! ! f l !  s ?s . t-, s i i s s ; - ! ? : ? : : ! : .? : ? ; : : ! :  !? -1%  s i 5
nn:ni«uii  s iiii^iiiiiiitiiip ,is |  fs j . HssliiHiiiiiiiiififill. 235 11*1 is
fs^ l^ l|jsel!!,32:sss3ss33ssfll§sslr .islil JssIMssiMSSssSsssssSssse Jds-ssssSsS Jsfl
» *
u
0
-p
pi
f t
s£ O
I I  O
5 : , = - O ^
::  5 '• I u 10Z S ■ ^ N ^ Q •
• £ j ?1 ?sf -  . J *  -H  CO
I  I ' f  : n .  i U U  ;. ;- v >y a
?: s L.r i £ =’ t £ - i  5 = S CQ O
H2 'r_1. •. ?i s ; ;a5:5' ?. ;5 5, i ;  leg -> pq o
*• -.I «* si I  n r  «  si?!?l ; i ?5 i  u  . |U !  : :  ® S
? ! V- 51 !?  I  *21. S ! * m m  |» .5  1! 7 I  c ' lM s 1 ' ? 1* n  ©
I1 \u,\\ :i 1 Ui IlIIMsii it is It ;\ ] IPIpi .,2 i , . . :sa; : i!?li $  g
ri.i«||!i I? -ssHL ihiUsnl'?**!? is o«'- ‘in?1 f m  i-mmsi*** “,5‘ £??I= -=   " ■*'_   _ _ . * C * «- * ♦ ♦ ♦ ♦ * . * ♦  S K «6 <sv?; si;? :;£? Josssssssss-S icq
8lsLusIH-s 1HH isl??IIIIISS! ^8 * 5 5 5 a ‘i;??£S££ ilrits tSSSJS£ = 5li*£-s^“- ,I' ,e
2 5;5iti:5:MM-i-i;uo;-. . ,u e a ^ n --0T--. >_ ^  CO
P CtJ
p
*n d
S fta P:
O P aJbC
x  o >»
I—I p -pQ ft "H
X >H CQ-H
ft -h p>
ft -P o
<3 ■ Eh
APPENDIX D ( i )
Program to obtain values for AO, Al, A2 and A3, as parameters 
for quench curve for 1210 Ultrobeta
10 REN NAME STANDARD PARAMETERS 
20 REN PROGRAHHER A/SCOTT  
30 REH DATE 2 4 . 0 7 . 8 0
40 REH T H I S  PR0GRAHHE CALCULATES THE C O E F F I C IE N T S OF THE GIVEN DATA
5 0  REM B E S T - F I T T I N G  THIRD DEGREE P0LYN0HIAL
60 REH E=A0+A1*R+A2*R*2+A3*R*3 BY THE HETH0D OF LEAST SQUARES
70 DEFINE FILE #1= 'SCOTT",ASC,120
71 REM AT FIRST N, THE TOTAL NUHBER OF POINTS.
72 REH THEN A, THE ACTIVITY.
73 REH THEN THE VALUES FOR R AND CPH IN TURNS.
75 REH INSERT DATA IN FILE t i l . AT FIRST N, THE TOTAL NUMBER OF POINTS 
80 REH AND A, THE ACTIVITY, THEN THE VALUES 
90 REH FOR R AND CPH IN TURNS.
95 DIM R<28)
100 READ ti l  ,N,A 
110 FOR H=1 TO 10 
120 S(H)=0 
130 NEXT H 
140 FOR 1=1 TO N 
150 READ t i 1 , R( I ) , C 
160 FOR J=1 TO 6 
170 S ( J ) = S ( J ) + R ( I ) * J  
180 NEXT J 
190 FOR K=7 TO 10’
200 S(K)=S(K)  + 10"0*C*R( I) A ( K - 7 ) / A  
210 NEXT K
215 PRINT 'R = / , R ( I ) / E  = '  , IN T<10A4 * C / A + . 5 ) / 1 0 0
220 NEXT I
230 D = S ( 2 ) - S ( 1 ) *2 /N
240 E = S ( 3 ) - S ( 1 ) * S ( 2 ) / N
250 F = S ( 4 ) - S ( 1) * S ( 3 ) / N
260 G = S ( 8 ) - S ( 1) * S ( 7 ) / N
270 A=EA2 - ( S ( 4 ) - S ( 2 ) " 2 / N ) * D
280 B = ( S ( 5 ) - S < 2 ) * S ( 3 ) / N ) * D - E * F
290 C = (S < ? ) -S (2 ) *S < 7 ) /N ) *D -E *G
295 0 = ( A * ( ( S ( 1 0 ) - S ( 3 > * S ( 7 ) / N ) * D - F * G ) + B * C )
300 A 3 = Q / ( A * ( ( S ( 6 ) - S ( 3 ) A2 / N ) * D - F * 2 ) + B "2 )
310 A2=(B*A3-C) /A
320 A 1 = (G -A 2 * t -A 3 * F ) /D
330 A 0 = ( S ( 7 ) - A 1 * S ( 1 ) - A 2 * S ( 2 ) - A 3 * S < 3 ) ) / N
335 PRINT
340 PRINT 'AO = ' , INT<10 * A 0 + . 5 ) / 1 0 
350 PRINT ' A l  = ' , I N T ( 1 0 * A 1 + . 5)710 
360 PRINT 'A2 = ' , I N T ( 1 0 * A 2 + . 5 ) / 1 0
370 PRINT 'A3 = ' , IN T (1 0 * A 3 + . 5 ) / 1 0
371 PRINT
3.72 FOR i=  1 TO N
i 7 4  Y = A 3 * R ( I ) A3 + A 2 * R ( I ) ‘ 2+A1*R( I ) +A0 
376 PRINT 'Y  = ' , I N T ( 1 0 " 2 * Y + . 5 ) / 1 0 0  
378 NEXT I  
400 END
APPENDIX D ( i i )
Quench curve obtained from d.p.m. package on RackBeta 
1215 * ’’
Ou6+JL+\ C^ l
EFF1Z RATIO
8947.0 25.06 1.312
8019.0 22.46 1.187
7492.0 20.99 1.146
4523.0 18.27 1.050
5985.0 16.76 1.009
4275.0 11.97 .848
2531.0 7.09 .672
1774.0 4.97 .525
1743.0 4.88 .591
1070.0 3.00 .460
PLOT QUENCH CURVES <R> ->R
IUSY CALCULATING
ISOTOPE 1. UINDOU 1
EFFZ
25.0*4 *|
I **»
I »*
I *
22.50+
I *
I 0*
I «*
2 0 . 00+ *
I « +
I «*
I *0
17.50+ «
I I
I •
I *«
15. 00+ «
I ♦«
I *
I **
12.50+ **
I
I *
I *»
10.00+ *•
I •
I *•
I *
7.50+ ♦*
I *0
I ♦
I +*
3.00+ •#«*«•*
I ••
I *
10
I
I------♦--------------♦-----------♦-------------♦-------------♦................♦................♦-------------♦............................0
.5 0 0  .A 00  .7 0 0  .0 0 0  .9 0 0  1.000  ' 1.100  1.200  1.300
